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Abstract 
Alternative pre-mRNA splicing is a powerful mechanism that is exploited by higher 
eukaryotes to diversify their proteomes, and to differentially regulate the expression, 
function, and localization of mRNA and proteins. Pre-mRNA splicing is typically 
regulated by RNA-binding proteins that recognize cis-acting RNA elements, and either 
activate or repress splicing of adjacent exons in a temporal, and tissue specific, manner. 
Understanding how RNA-binding proteins control the splicing code is fundamental to 
understanding organismal development and disease. 
The SR proteins are a well-conserved class of RNA-binding proteins that have an 
essential role in the regulation of splice site selection, and have also been implicated as 
key regulators during other stages of RNA metabolism. The complexity of the RNA 
targets, and specificity of RNA binding location remains poorly understood for many 
members of the SR protein family. Here, we present a comprehensive study to elucidate 
how the SR proteins coordinate to regulate alternative pre-mRNA splicing (AS) in 
Drosophila.  
Genome-wide analysis of SR-dependent splicing by RNA-seq, reveals that SR proteins 
are required for the regulation of many types of alternative splicing events, and can act as 
positive or negative regulators of splice site choice depending on their binding location 
on the target RNA. In addition, a vast majority of regulated targets require multiple SR 
protein members for regulation. RNAi of multiple SR proteins simultaneously results in 
an additive change in the magnitude of splicing. This indicates that SR proteins co-
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regulate alternative splicing events in a combinatorial manner through binding specific 
locations on the target transcripts.  
Using single-nucleotide resolution UV cross-linking and immunoprecipitation (iCLIP), 
we define the specific RNA-binding maps of the entire family of SR proteins in the 
transcriptome of Drosophila S2 cells. We find that SR proteins bind a distinct, but 
functionally diverse, class of RNAs that includes mRNAs, both constitutive and 
alternatively spliced, as well as non-coding RNAs.  Closer analysis of the bound 
transcripts revealed that while individual SR proteins can bind unique transcripts, 
multiple SR protein family members bind a majority of the target transcripts. 
This comprehensive analysis reveals position-dependent RNA splicing maps, in vivo 
consensus binding motifs, and a high level of cross- and coordinated regulation of 
alternative splicing by the SR protein family.  
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Chapter I:  Introduction 
1.1 Introduction 
After transcription, the removal of non-coding sequences, introns, from the pre-mRNA 
by pre-mRNA splicing allows the coding sequences, exons, to be spliced together to form 
functional mature RNAs (mRNAs). This process is an essential step for gene expression 
in higher eukaryotes. Alternative splicing (AS) is the process of generating multiple 
mRNA isoforms from a single pre-mRNA by joining exons together in different 
combinations. 
1.2 Pre-mRNA Splicing 
Pre-mRNA splicing takes place in two transesterfication reactions (Figure 1.1). In the 
first step, the 2’-hydroxyl group of the adenosine at the branch point attacks the 
phosphate at the 5’ splice site.  This results in the detachment of the 5’ exon, and an 
intron-lariat attached to the 3’ exon. The next step proceeds with the attack of the 3’ 
hydroxyl group of the 5’ exon on the phosphate bond at the 3’ splice site, resulting in 
release of the intron lariat, and ligation of the exons [1]. 
A macromolecular complex termed the spliceosome carries out the splicing reaction.  The 
spliceosome consists of five small nuclear ribonucleoprotein particle (snRNPs), and 
hundreds of accessory protein components [2, 3]. The spliceosome recognizes sequence 
elements within the intron that define the intronic boundary, and promote excision of the 
intron at precise locations. Assembly of the spliceosome is initiated by recognition of the 
5’ and 3’ splice sites by U1 snRNP and U2AF (U2 snRNP auxiliary factor), respectively  
	   2	  
 
Figure 1.1: Catalytic steps of pre-mRNA splicing. Pre-mRNA splicing is carried out in 
two transesterfication reactions. The first reaction results in the release of the first exon 
and formation of an intron lariat fused to the second exon. The second reaction produces 
spliced exons and a liberated intron lariat.  
 
(Figure 1.2). This results in the formation of the E complex. Next, the U2 snRNP is 
recruited to the branch point sequence, in an ATP-dependent manner, resulting in A 
complex formation [4]. This leads to the subsequent recruitment of the U4, U5, and U6 
tri-snRNP forming the B complex. The B complex undergoes a series of complex 
rearrangements that allows for the formation of the C complex, and a catalytically active 
spliceosome. The C complex leads to splicing, release of the intron lariat, and subsequent 
spliceosomal recycling [5]. Splicing together exons can be either constitutive (when the 
exon is always a part of the final mRNA transcript), or alternative (when the exon is not 
always included in the final mRNA). 
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Figure 1.2: Spliceosome assembly. During E complex formation the U1 snRNP and 
U2AF bind the 5’ and 3’ splice sites, respectively. Next, the U2 snRNP binds the branch 
point (A) and forms the A complex. Recruitment of the U4/U6 • U5 tri-snRNP forms the 
B complex. This leads to a series of structural rearrangements and formation of the 
catalytically active spliceosome.  
 
1.3 Alternative pre-mRNA splicing of metazoan genes 
Recent sequencing of higher eukaryotic genomes revealed that Drosophila melanogaster 
and Canaerhabditis elegans have ~14,000 and ~38,000 protein coding genes, 
respectively, while there are ~51,000 protein coding genes in the human genome [6]. This 
suggests that there is little correlation between the number of genes in an organism’s 
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genome, and the biological complexity of the organism. It has been proposed that other 
genomic features, such as alternative splicing, can account for the differences in 
complexity by expanding the coding capacity of the genome [7]. AS significantly 
expands the diversity of the proteome by producing multiple mRNA transcripts from a 
single protein-coding gene [8].  Recent estimates suggest that greater than 90-95% of 
human multi-exon transcripts can undergo AS [9]. In addition to expanding the proteome, 
AS is utilized to regulate gene expression, as many of the mRNA variants are expressed 
differentially between tissues, cell types, and developmental conditions [10].  
Over the past decade, instances of AS controlling important physiological pathways have 
been characterized, one of which is the sex determination pathway in Drosophila 
melanogaster [1, 11, 12]. Sex lethal (Sxl) is an RNA-binding protein that is expressed 
specifically in female flies, where it represses down-stream splicing patterns of other 
splicing and transcriptional regulators, that would lead to male development (Figure 
1.3A) [13]. Regulation of Sxl, and other splicing regulators control sex determination in 
Drosophila.  The idea that AS splicing is an important regulatory mechanism can be 
extended to other organisms, in mammalian cells, there is a specific isoform of the SRC 
tyrosine kinase that is activated in neurons (n-src), and repressed in non-neuronal cells (c-
src). Splicing control of this event is attributed to neural specific splicing regulators 
nPTB, Fox-1/2, and generally expressed splicing regulators hnRNP H, hnRNP F, and 
ASF/SF2 (Figure 1.3B) [14-16]. It has been hypothesized that the different SRC variants 
have different interacting partners, and therefore, different physiological functions 
between different tissue types.  Given the pervasiveness of AS, and that proper control is 
essential for tissue development and homeostasis, it is important to understand the 
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mechanism of AS regulation, especially since misregulation of specific AS events have 
been shown to directly cause several genetic diseases.  
1.4 Alternative splicing and disease 
Approximately 15% of mutations that result in genetic disease affect sequence elements 
important for pre-mRNA splicing [17]. One well-studied example is Spinal muscular 
atrophy (SMA) in humans. SMA is a severe neurodegenerative disorder that results from 
lack of survival of motor neuron 1 (SMN1) protein.  Survival of motor neuron 2 (SMN2) 
is a paralogous gene that differs from SMN1 by a single nucleotide change (C>T 
transition in exon 7), which results in the increased skipping of exon 7, and the increased 
production of a non-functional protein (Figure 1.3C). It is believed that this nucleotide 
change results in either the disruption of an exonic splicing enhancer, or the creation of 
an exonic splicing silencer [18, 19].  Several therapeutic approaches are aimed at 
inducing higher inclusion of exon 7 of SMN2 to produce more functional SMN protein in 
affected patients [20, 21]. 
Additionally, mutations that affect the AS of tumor suppressors, leading to their 
inactivation, are responsible for a variety of inherited and sporadic cancers. One of the 
earliest discovered examples of AS regulation in cancer was the regulation of Bcl-X 
(Figure 1.3D).  Bcl-X pre-mRNA can be alternatively spliced to produce a long isoform 
(Bcl-X (L)), which has anti-apoptotic effects, and a short isoform (Bcl-X(S)) which 
promotes apoptosis [22]. High Bcl-X L/S ratios are observed in a variety of cancer types, 
consistent with an important role for Bcl-X (L) in cancer cell survival [23, 24]. Often, 
aberrant expression of splicing factors in cancer cells contribute to the change in AS 
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observed in tumor suppressors [25, 26]. For example, it was observed that Sam68 
overexpression resulted in an increase in Bcl-X(S) isoform, and had a pro-apoptotic 
effect [27].  Therefore, understanding the physiological targets, and the molecular 
mechanism of action of splicing regulators, will be important for development of novel 
strategies to treat splicing-associated disease.  
1.5 Patterns of alternative splicing 
Common patterns of AS have been observed and are used to classify alternative splicing 
into five simple types (Figure 1.4) [1, 28]. The most commonly studied forms of AS are 
cassette exon splicing events. This occurs when an entire cassette exon is included or 
skipped in the resulting mRNA. There are also competing 5’ splice sites and 3’ splice 
sites, where only a portion of the exon is included or skipped. Mutually exclusive exon 
AS occurs when two or more adjacent cassette exons are spliced such that only one exon 
in the group is included at a time. The most frequent form of AS observed in D. 
melanogaster are intron-retention events (Figure 2.4B).  This is when the entire intron is 
removed or retained. This form of AS is less common in mammals, perhaps due to the 
longer length of introns that would significantly disrupt the protein coding sequence if 
retained. Finally, there are alternative first exons and alternative last exons. These events 
are uniquely regulated, because they do not solely rely on changes in splice site usage. 
Alternative transcriptional promoter usage, or alternative transcription termination and 
polyadenylation, influence the outcome of these events. A single pre-mRNA can exhibit 
multiple sites of alternative splicing using these simple patterns, in a combinatorial 
manner, to produce multiple mRNA isoforms.  
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Figure 1.3: Schematic representations of AS events important for development and 
disease. (A) SXL (blue oval) is a female-specific splicing factor that regulates the 
splicing of targets in the Drosophila sex determination cascade that contribute to female 
attributes, such as, Transformer. (B) SRC tyrosine kinase has a neuronal expressed 
isoform that is regulated by the splicing regulators nPTB (blue oval), hnRNP H/F (green 
oval) and others. (C) SMN2 has a single nucleotide polymorphism that results in the 
skipping of exon 7, and results in nonfunctional SMN protein. This splicing event is a 
therapeutic target for SMA patients hoping to restore SMN protein production. (D) BCL-
X AS produces a long isoform (BCL-X (L)) that is anti-apoptotic, and a short isoform 
(BCL-X (S)) that is pro-apoptotic. Several tumors preferentially express the long isoform 
and evade apoptosis.  
 
1.6 Regulation of Alternative pre-mRNA Splicing 
The sequences of the pre-mRNA elements recognized by the splicing machinery to 
catalyze intron removal are highly degenerate, and therefore occur frequently within the 
genome, despite being ignored by the spliceosome (Figure 1.5). The sequences of the 
splice sites within the intron can be classified as “strong” or “weak” depending on their 
similarities to the consensus splice site motifs, which reflect the strength of recognition 
by components of the spliceosome. Introns with strong splice sites are efficiently 
recognized by the spliceosome, and constitutively spliced. Introns with weak splice sites 
are often alternatively spliced, or require additional regulatory signals for proper splicing 
[29]. Therefore, in addition to splice sites, other splicing regulatory elements (SREs) 
within the pre-mRNA are required for proper splicing efficiency, and control of AS 
(Figure 1.5) [30, 31].  Exonic splicing enhancers (ESEs) and intronic splicing enhancers 
(ISEs), are bound by RNA-binding proteins that subsequently recruit, and/or promote, the 
assembly/stability of spliceosomal components, which consequently activate the use of 
nearby splice sites. Similarly, exonic and intronic splicing silencers (ESSs and ISSs, 
respectively) are bound by factors that inhibit the use of nearby splice sites [1, 32]. The  
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Figure 1.4: Common patterns of alternative mRNA processing. Black boxes represent 
constitutive exons. Red and blue boxes indicate alternative exons. Thinner portions of 
alternative exons indicate untranslated regions (UTRs). Red and blue lines correspond to 
the two outcomes alternative splicing. 
 
specific combinations of these elements, their proximity to splice sites in conjunction 
with the specific trans-acting factors expression levels, determine which splice sites are 
used, and contribute to the proper splicing outcome. Besides the splice site consensus  
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Figure 1.5: Cis-elements in a pre-mRNA important for proper splicing control. 
Exons are represented as rectangle boxes. 5’ and 3’ splice site dinucleotides represent the 
intron boundary (GU-AG, respectively). The branch point, A, and the polypyrimidine 
tract, Py, sequences are also crucial for splice site recognition. Exonic and Intronic 
splicing enhancers (ESE, ISE) and silencers (ESS, ISS) are important splicing regulatory 
sequences that can vary in length and position on the pre-mRNA. 
 
sequences and SREs, RNA secondary structure, RNA polymerase processivity and rate, 
and epigenetic chromatin marks can influence splice site selection [33, 34]. 
1.7 Trans-acting splicing regulators 
There are many groups of splicing regulatory proteins that bind to cis-elements in the pre-
mRNA to control splice site selection. One class of RNA-binding proteins are proteins 
that contain arginine-serine rich (RS) domains. Members of the serine-arginine rich (SR) 
protein family are in this group, and are thought to be general activators of splice site 
selection by binding to enhancer sequences in the pre-mRNA (ESEs and ISEs) [35]. 
Another well-conserved class of splicing regulators is the hnRNP family. Members of the 
heterogeneous nuclear ribonucleoprotein (hnRNP) family do not have an RS-domain, and 
are generally characterized as repressors of splicing by binding silencing elements in the 
pre-mRNA (ESSs and ISSs) that block spliceosome assembly, or antagonize splicing 
activators, such as SR proteins [36]. In addition to the well-characterized SR and hnRNP 
protein families, there are a number of unrelated splicing regulators that function in a 
tissue specific manner, such as the RNA-binding proteins NOVA and FOX [37]. The 
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regulation of AS by many proteins remains poorly understood, as are the contributions of 
other protein families that do not bind RNA, such as chromatin remodelers. 
1.8 The Serine/Arginine-rich family (SR proteins) 
The SR protein family is an essential, highly conserved, class of splicing regulators. SR 
proteins are characterized as having one or two N-terminal RNA recognition motifs 
(RRM), and a C-terminal domain enriched in arginine and serine dipeptides (RS-
domain). In humans, this definition has identified 12 canonical SR proteins, and dozens 
of related SR-like proteins that contain an RS-domain, but lack a defined RRM were 
found [38]. The number of introns that interrupt eukaryotic genes varies greatly between 
organisms. Since SR proteins have been associated with regulation of splicing, it was 
predicted that the number of SR protein family members would increase with the number 
of intron-containing genes. Indeed this correlation exists; only two SR proteins have been 
found in S. pombe, seven SR proteins in C. elegans, and 12 SR proteins in humans.  In 
Drosophila, there have been eight SR proteins identified, and they are highly homologous 
to their mammalian counterparts (Figure 1.6) [39]. SR proteins were first identified as 
essential components of the splicing reaction, because of their ability to complement 
splicing deficient cytoplasmic S100 extracts [40, 41].  SR proteins have since been 
implicated in the regulation of a large number of AS events, and participate in all crucial 
aspects of RNA metabolism, including mRNA export, localization, translation, and 
nonsense mediated decay (NMD) [42-45].  
To explore SR protein roles in organismal development, animal and insect knockout 
models were engineered for several members of the SR protein family. Surprisingly, SR  
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Figure 1.6: SR protein paralogs. Drosophila and mammalian SR proteins share extreme 
sequence similarity and conservation. 
 
protein-null mice for three SR proteins (SC35, ASF/SF2, and SRp20) all showed early 
embryonic lethality [46]. Previously, it was thought that SR proteins had redundant 
functions, because of the ability of multiple SR proteins to complement splicing deficient 
S100 extracts. Since each SR-null mouse shows lethality when only a single member of 
the SR protein family is knocked-out, this provided evidence that SR proteins are not all 
functionally redundant, and individual SR proteins have specific roles during 
development. However, embryonic fibroblasts derived from these mice are viable. This 
indicates that, individually, SR proteins are not essential for cellular viability, but rather 
function tissue specifically and are critical for precise developmental decisions. In 
addition to mammalian development, knockout of the Drosophila melanogaster SR 
protein B52 also had deleterious effects on development, as B52-null mutants do not 
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develop past the second-instar larval stage [47]. This observation also supports the non-
overlapping roles that specific SR proteins have in vivo. 
To bypass embryonic lethality, conditional knockout mice have been engineered. 
Conditional deletion of SC35 in the thymus and heart was shown to cause a defect in T-
cell maturation, and to induce dilated cardiomyopathy [48]. Similarly, deletion of 
ASF/SF2 in the heart caused a hyper-contraction phenotype due to defects in post-natal 
heart remodeling [49]. Both alternative splicing and gene expression profiles are changed 
in these mutant tissues, and are thought to contribute significantly to the phenotypes 
observed. Conditional knockout of B52 in Drosophila eye tissue resulted in flies with 
small eyes. This was attributed to B52 regulation of an AS event of a master regulator of 
eye development, eyeless, resulting in a protein isoform that gives rise to small eyes [50].  
Additionally, expression of SR proteins is up-regulated in certain human tumors. Tumors 
in the lung, ovary, breast, kidney, colon, liver, and pancreas all showed elevated SR 
protein levels [25, 51, 52]. These studies demonstrate the vital role that SR proteins play 
in embryogenesis and tissue homeostasis, and further stress that the understanding the 
molecular targets, and mechanism of SR protein regulation, is crucial to our 
understanding of organ development and disease progression.  
SR proteins are though to be general activators of splice site selection by binding to ESEs 
in the pre-mRNA (Figure 1.7). Once bound, SR proteins can recruit and/or stabilize  
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Figure 1.7: Roles of SR proteins in constitutive and alternative splicing. (A) SR 
proteins bound to ESE elements in the pre-mRNA can recruit and/or stabilize 
components of the spliceosome (U1 snRNP and U2AF) in a process know as exon 
definition. (B) SR proteins can antagonize splicing repressors bound to ESS elements, 
and promote splice site selection. (C) Through RS domain interactions SR proteins can 
help bridge the intron, and bring the 5’ and 3’ splice sites in close proximity for more 
efficient splicing.  
 
components of the splicing machinery, such as the U1 snRNP to the 5’ splice site or 
U2AF to the 3’ splice site, through RS-domain protein-protein interactions (Figure 1.7A)  
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[53-55]. SR proteins can also form a network of protein-protein interactions across 
introns to juxtapose the 5’ss and 3’ss, to facilitate early spliceosome assembly (Figure 
1.7C) [56].  Typically, SR protein binding sites, and binding sites of other splicing 
regulators, such as the hnRNP family, are in close proximity, suggesting that the interplay 
between activation and repression modulates the frequency of exon inclusion (Figure 
1.7C) [57].  
SR protein binding to target sequences in the pre-mRNA are mediated by interactions in 
the RRM-domain. Using in vitro binding studies, there is compelling evidence that 
individual SR proteins can have different, functionally significant, RNA-binding sites 
[58]. Also, It has been demonstrated that the position of SR-protein binding sites in the 
pre-mRNA determines whether these sites will function as enhancers or silencers of exon 
inclusion [59]. It was also shown that the activation of exon inclusion was proportional to 
the number of RS dipeptide repeats within the RS-domain of the bound SR protein [60].  
In addition, the frequency of exon inclusion for many AS events is determined by the 
binding position of multiple RNA splicing factors, including multiple SR protein family 
members. For example, SR proteins 9G8, ASF/SF2, and Rbp1 cooperatively bind with 
the splicing regulators Tra and Tra2 to specific locations on the Drosophila doublesex 
transcript to regulate sex-specific AS [61]. Also, hnRNP A1 and the SR proteins 
ASF/SF2 and SC35 have antagonistic functions in the splicing of the mammalian ß-
tropomyosin transcript [62].  
In order to bind RNA and function in AS, SR proteins require the phosphorylation of 
their RS-domain [63]. A number of SR protein kinases, such as SR protein kinase 1 
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(SRPK1) and Clk/Sty kinase, are able to phosphorylate serine residues within the RS-
domain [64, 65]. Modification of the RS-domain is also used as a means of regulating SR 
protein localization to the nucleus. Some SR proteins shuttle between the nucleus and 
cytoplasm, and reversible phosphorylation has been identified as one regulatory 
mechanism of this shuttling.   
In addition to their role in regulating AS of pre-mRNA, SR proteins function in mRNA 
processing steps that occur after splicing. SR proteins, SRp20, 9G8, and ASF/SF2, have 
been shown to interact with the mRNA nuclear export receptor TAP/NFX1, and promote 
nuclear export of histone mRNAs [66, 67]. SR proteins have also been shown to 
influence translation. ASF/SF2 indirectly influences translation initiation by promoting 
the production of an isoform of the protein kinase, MNK2, which enhances cap-
dependent translation [25]. ASF/SF2 is also involved in regulating translation directly 
through recruitment of components of the mammalian target of rapamycin (mTOR) 
signaling pathway [68]. SRp20 and 9G8 have also been implicated in increasing 
translation efficiency of viral and intronless mRNAs, respectively [69, 70]. In addition to 
translational regulation, SR proteins have been found to affect other RNA-processing 
steps. For example, the Nonsense-Mediated Decay (NMD) is a pathway that targets 
mRNAs containing premature termination codons for degradation. Increased expression 
of many SR proteins (ASF/SF2, SC35, SRp40, and SRp55) strongly enhances the NMD 
response [71]. SR proteins have also been implicated in transcriptional control. For 
example, the SR protein SC35 has been shown to associate with active chromatin, and 
affect transcriptional elongation by recruiting kinases to Pol II, independent of its role in 
AS [72]. These findings demonstrate that SR protein function is not restricted to nuclear 
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mRNA splicing, but play substantial roles in downstream mRNA metabolic functions in 
the cytoplasmic compartment.  
1.9 Methods for the genome-wide detection of alternative splicing  
Advances in technology have created the ability to explore and assay alternative splicing 
in a genome-wide manner. Various platforms for high-throughput detection of changes in 
AS have been developed, and contribute substantially to the identification of known 
splice variants in a given tissue, or that are changed under specific cellular conditions, 
like stress or stem cell differentiation [9, 73]. They have also been used to identify AS 
events regulated when a specific factor’s expression is manipulated [74, 75]. There are 
two main technologies that are currently utilized to profile genome-wide splicing 
changes: splicing-sensitive microarrays and next-generation sequencing (also known as 
RNA-Seq).  
A microarray consists of a glass slide with thousands to millions of oligonucleotides 
anchored to hybridize to transcripts that contain sequences of interest. Typically, RNA is 
isolated from a source (Tissue or specific cell type), and polyadenylated mRNA is 
enriched. Selected mRNA is subjected to reverse-transcription polymerase chain reaction 
(RT-PCR). The resulting cDNA is labeled with a fluorescent dye, hybridized to the 
microarray, and signal intensity is quantified at positions on the array where the sample is 
bound with the probe sequence. The intensity of the signal at each probe location on the 
microarray is proportional to the amount of mRNA that was in the sample. In order to 
detect changes in AS, microarray probes must be also designed to include splice 
junctions.  Changes in probe intensities at the splice junctions for different experimental 
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conditions indicate AS changes. A limitation to using microarrays to detect changes in 
AS, is that profiling is restricted to annotated, or known, AS events. Also, due to the 
limited number of probe sets that can fit on a microarray, it is not possible to design 
probes to detect all possible AS outcomes. This limits the number of AS events that can 
be assayed, and prevents the discovery of novel, unannotated, AS events.  Another 
drawback is the signal is measured indirectly, as a fluorescent signal, therefore 
differences in probe specificities, and other noise variables, can affect the readout [76, 
77]. 
RNA-Seq is the newest high-throughput method to detect AS. RNA-Seq provides an  
approach to directly sequence millions of cDNAs generated from an RNA sample in a 
short amount of time, and at a small cost. There are many next-generation sequencing 
platforms used for RNA-Seq, and other high-throughput genomic applications. However, 
one of the most widely adopted platforms, and the platform used in the studies described 
in this dissertation, is Illumina sequencing. To prepare a sample for Illumina sequencing, 
mRNAs are selected by affinity purification using poly(T) oligos. Next, the mRNA is 
fragmented, and converted to cDNA using a random hexamer primer. After second strand 
synthesis, Illumina sequencing adapters are ligated onto the ends of the cDNA molecules, 
then the library is PCR amplified, and size selected at ~260bp. The resulting cDNA 
library is then sequenced starting from the ends of the molecule, and the number of base 
pairs sequenced depends on the number of sequencing cycles [78]. RNA-seq typically 
produces millions of short sequences known as “reads.” Currently, Illumina can sequence 
35-100bp, but this technology is rapidly advancing and the total number of sequence 
reads, and the length of the read, is expanding exponentially.  
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In contrast to array-based methods, RNA-Seq does not rely on predesigned probes, and 
therefore can identify and quantify all the RNAs present in a sample, without the need to 
know the sequences beforehand.  This allows for the identification of new AS events that 
were not known to exist [79]. This is also useful for profiling a transcriptome from an 
organism that is not well annotated [80]. A second advantage of RNA-Seq, is its low 
background signal, and consequently,  greater dynamic range of expression detection [76, 
78]. This allows for the detection of changes in gene expression and AS in low expressed 
transcripts. 
Like many other high-throughput technologies, RNA-Seq faces several bioinformatic 
challenges. The data that is produced from an RNA-seq run is increasingly large, and 
several quality controls have to be implemented to reduce errors in base-calling, and 
removing low-quality reads [81]. One of the first steps of analyzing high-quality RNA-
Seq data is to align the reads to a reference genome. Software has been developed to 
assist in aligning millions of short reads to the genome, rapidly. Bowtie is one alignment 
program that can align reads to the genome in a short amount of time [82]. One problem 
with Bowtie is that it allows mismatches, but not gaps in the alignment. While this is not 
a problem for most positions on the genome, reads that fall over splice junctions will not 
align using Bowtie. One solution is to create a database of known or predicted splice 
junctions, and then align the reads that did not align to the genome, to the database of 
splice junctions. As sequencing reads get longer, it will become more likely to have reads 
fall within the splice junctions, therefore a future challenge is to develop computational 
methods to simply align reads falling in splice junctions. Next, aligned reads are assigned 
to specific transcript isoforms, and then the number of reads within each isoform is 
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quantified. This allows for the quantification of changes in alternative splicing, or 
assaying changes in entire transcript isoforms [83-85]. 
RNA-Seq has clear advantages over previously developed high-throughput platforms, 
such as splicing-sensitive microarrays. It not only provides a more sensitive, unbiased, 
approach to analyzing AS, but also can be used to monitor other transcriptional changes. 
In addition to AS, information about transcript expression, stability, 5’ and 3’ end 
formation, can all be obtained from a single RNA-Seq experiment [78, 86]. 
1.10 Identification of the genome-wide RNA binding distribution of splicing       
factors 
Multiple factors are important for the regulation of AS.  RNA attributes, such as RNA 
structure and binding of noncoding RNAs, have been demonstrated to influence AS 
outcomes [87, 88]. However, protein-RNA interactions are considered the primary 
method of AS regulation, and to understand how splicing is regulated, it is important to 
know what RNA elements splicing regulators interact with to function in AS. 
A number of computational approaches have been used to identify sequence motifs that 
regulate exon inclusion. The RESCUE-ESE (relative enhancer and silencer classification 
by unanimous enrichment) method analyzed motifs that occur within exons with a 
difference in splice site strengths, and identified 238 putative ESEs that occurred more 
frequently in exons with weak splice sites [89]. Another study compared exons with 
pseudoexons, and identified 2000 RNA octamers that were found more frequently in 
exons that are spliced [90]. More recently, bioinformatic studies have been performed on 
genome-wide data sets that identify RNA motifs that are enriched around alternative 
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exons that are regulated tissue specifically, or are changed in different developmental 
stages [83, 91]. Many of the putative ESE sequences were shown to enhance exon 
inclusion in vivo.   
In conjunction with identifying regulatory sequences in the RNA, several approaches 
have been taken to identify the RNA motifs that are recognized by specific splicing 
regulators. One approach, SELEX (selected evolution of ligands through exponential 
enrichment), selects for high-affinity binding sites by assaying protein binding to a 
randomized pool of RNA sequences [92]. This has resulted in the identification of 
binding sites for many splicing regulators, including some members of the SR protein 
family [93-95]. Since these motifs are derived in vitro, an alternative approach, termed 
functional SELEX, was developed and allows for selection of binding sites from random 
sequences inserted into a mini-gene reporter construct. Functional SELEX allows for 
selection of sequences that regulate splicing, in vivo, rather than just RNA binding alone 
[96]. The enriched binding sites for splicing regulators derived from SELEX and 
functional SELEX were analyzed for their presence near alternative exons, and were used 
to predict exons regulated by several RNA-binding proteins. 
The biochemical methods used to identify protein-binding sites were useful for predicting 
regulated exons, but these approaches did not assay RNA binding by native proteins in an 
intact cellular context. RNA immunoprecipitaion (RIP) combined with RT-PCR or 
microarray technology was the first step to identify native protein-RNA interactions [97]. 
However, this approach is limited by low resolution of binding sites, and common 
identification of indirect interactions with the RNA. Additionally, reassociation of RNPs 
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after cell lysis complicated the ability to classify interactions as a true reflection of RNA 
binding, in vivo [98].  
In order to increase binding site specificity and resolution, CLIP (cross-linking and 
immunoprecipitation) was developed. The CLIP procedure involves the in vivo UV cross-
linking of RBPs to their target RNA molecules, this allows for purification of RNP 
complexes under stringent, denaturing, conditions [99]. When the resulting bound RNAs 
are subjected to next-generation sequencing (CLIP-Seq), genome-wide protein-RNA 
interactions can be identified [100]. This allows for the identification of, in vivo, specific 
and direct protein-RNA interactions that can reveal global principles of RBP function.  
This procedure was first used to characterize the RNA binding targets of the neuronal-
specific splicing factor, Nova, but have since been used for many other RBPs, including 
the mammalian SR protein ASF/SF2 [101]. Although CLIP experiments produce data 
that is highly specific, cDNA libraries produced from CLIP have limited complexity. 
This is due to the inefficiency of UV cross-linking, and loss of complexity from 
inefficient steps in the library preparation [102]. Several modifications to the CLIP 
protocol have aimed at increasing the complexity, and specificity, of libraries being 
generated. Including, the use of photoreactive ribonucleoside analogs (PAR-CLIP), and 
modifications to the standard CLIP library preparation protocol that not only increases 
library complexity, but also allows for mapping of protein-RNA interactions at single-
nucleotide resolution (iCLIP) [103, 104]. It was observed that many cDNAs prematurely 
end at the cross-linked nucleotide [105]. In order to capture the truncated cDNAs, the 
cDNAs generated from iCLIP are circularized, and then sequenced from the cross-linked 
nucleotide position. The use of a more efficient cDNA circularization step increased the 
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library complexity, and allows for the mapping of protein-RNA interactions at the single-
nucleotide level. This technique has allowed for unprecedented resolution, and insight, on 
binding positions of many splicing regulators [106, 107]. Although many targets of 
regulators have been identified using one or more of these strategies, most of the targets 
of many RBPs are unknown. 
1.11 Integrating genome-wide datasets: RNA splicing maps 
Many early studies of AS focused on the regulation of a small number of splicing events, 
and characterized the mechanism of regulation of only a few splicing regulators. This 
means that many general conclusions about splicing regulation are supported by only a 
few examples. For example, SR proteins were thought to only enhance exon inclusion, 
and hnRNP family members silenced this enhancement. This general splicing conclusion 
was supported by analysis of minigene constructs of a few AS exons, using only a few 
members from each splicing factor family. However, over time, as SR and hnRNP 
proteins were studied more deeply, exceptions to this rule were uncovered [74]. SR 
proteins were found to have the ability to repress splicing when bound to certain intronic 
regions, and hnRNPs could enhance exon inclusion if bound downstream of the 5’ss 
[108, 109]. These results indicated that the binding position of splicing regulators on their 
targets determined how they functioned in regulation of AS. Therefore, to uncover the 
general principles of splicing regulation, multiple, genome-wide data sets need to be 
integrated.  
Combining identification of genome-wide changes in AS that are regulated by an RBP, 
and the RBP’s binding location on the target, yields splicing profiles that provide insight 
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into position-dependent regulation of AS (RNA splicing maps) [110]. The initial 
approach mapped the location of bioinformatically derived Nova binding sites around 
cassette exons that were found to be regulated by Nova using splicing-sensitive 
microarrays [111]. A comparison of binding location on the target transcript when Nova 
inhibited exon inclusion, and when it enhanced exon inclusion, revealed that Nova 
inhibited splicing when bound upstream of alternative exons, and activated inclusion 
when bound downstream. RNA splicing maps have since been generated using RNA-Seq 
and CLIP-Seq high-throughput datasets, and have detected the same primary positions of 
Nova binding near regulated exons [99, 100]. Similar RNA splicing maps have been 
generated for mammalian hnRNP family members, PTB, Fox 1/2, and the Drosophila 
Nova homologue Pasilla [83, 112-114]. Comparing the splicing maps of different RBPs, 
including comparing the maps of RBPs within the same family, can identify common 
principles of splicing regulation. Nova, Fox 1/2, and PTB can all silence exon inclusion 
by binding near the branch points or splice sites. RNA splicing maps for six members of 
the mammalian hnRNP family revealed that each hnRNP protein had a unique pattern of 
binding around regulated cassette exons to both activate or silence inclusion. The 
development of RNA splicing maps allows for the understanding of broad principles of 
splicing regulation, as well as, identifies proteins and targets that deviate from these basic 
models.  In addition, building RNA splicing maps for multiple RBPs will identify 
relationships and interactions between multiple splicing regulators on the same pre-
mRNA, and will reveal insights as to how combinatorial splicing control is achieved.  
Further integrating splicing maps with transcription, chromatin dynamics, RNA structure, 
and post-translational modification information will allow for understanding of how an  
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Figure 1.8: Uncovering the splicing code. The splicing code dictates the splicing pattern 
of a given pre-mRNA under a specific condition. RNA features, such as regulator binding 
sites and structure, and information about the location of splicing (tissue, stage, or disease 
state) are used to predict how spicing will be regulated.  
 
exon will be spliced in a certain tissue, developmental state, or specific condition, what is 
termed the splicing code (Figure 1.8). The splicing code will describe how RNA features 
work together to regulate splicing in a specific context, and provide further insights into 
the mechanism of misregulation in disease. 
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1.12 Discussion 
The precise control of AS by RBPs is essential for proper gene expression, and defects in 
regulation can result in severe genetic diseases and cancer. Our mechanistic 
understanding of AS has come from analyzing how trans-acting protein factors interact 
with cis-elements in target RNAs to regulate AS. More recently, it has been demonstrated 
that most AS events are regulated by multiple protein factors in a combinatorial, tissue 
specific, fashion. Therefore, understanding how multiple RBPs regulate the same AS 
event will provide clues as to how combinatorial regulation is achieved. 
ASF/SF2 was the first SR protein identified to have activity in constitutive splicing, and 
the ability to modulate AS [42].  Additional RS-domain containing proteins, with an N-
terminal RRM domain organization were identified, and termed SR proteins. Further 
studies demonstrated that other SR proteins could also function in splicing [115]. Most 
SR protein family members have been implicated in AS regulation, but many of the 
studies have been performed using in vitro systems, or modeled on single genes. There 
has never been a systematic genome-wide analysis of AS for a majority of the SR protein 
family members. Recent advances in the ability to rapidly characterize AS have allowed 
for a more comprehensive analysis of AS. It is now possible to use RNA-Seq to identify 
genome-wide AS events, and immunoprecipitation approaches to identify the precise 
binding location of RNA binding proteins across the transcriptome. 
In summary, work from many different systems has provided insight into the molecular 
mechanisms of SR protein regulation of AS. It has also been shown that SR proteins have 
specific functions during embryonic development and tissue maintenance, and that 
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mutations and aberrant expression of certain SR proteins play significant roles in the 
development and progression of many human diseases. In the coming chapters, we utilize 
RNA-seq following RNAi (RNA interference) of the eight identified SR proteins in 
Drosophila melanogaster–SC35, SF2, SRp54, XL6, Rbp1, B52, Rsf1, Rbp1-like–to 
identify AS events regulated by individual SR proteins, and reveal that a majority of SR 
regulated AS events are regulated by multiple SR proteins in an combinatorial manner. 
Additionally, we find that SR proteins can regulate other RNA processing events such as 
transcript abundance, alternative promoter selection, and alternative polyadenylation. 
Next, we show that AS regulation requires an SR protein RS-domain, and the RRM- 
domain confers SR protein specificity. Using iCLIP-Seq, we identify direct RNA binding 
sites across the transcriptome for each SR protein, including position-dependent binding 
locations that contribute to the regulation of AS events. Finally, we integrate the two 
genome-wide data sets to produce RNA splicing maps for the SR protein family. By 
comparing the RNA bound by individual SR proteins, and the pre-mRNAs controlled by 
them, we will begin to define precise global regulatory networks for this family of 
splicing factors. From this analysis, and analyses of associated proteins, we will begin to 
understand the exact molecular mechanisms used by SR proteins to regulate AS. These 
findings will present new insights into gene expression regulation, and the contribution of 
AS to development and disease.  
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Chapter II: Identification and Quantification of SR Protein Regulated RNA 
Processing Events Using RNA-Seq 
2.1 Introduction 
Most of our understanding of how SR proteins regulate AS come from biochemical 
studies focused on single genes, and in vitro assays. These studies have provided a 
general understanding of the mechanisms of splicing regulation by the SR proteins, but 
only using a few SR protein family members, and a small number of alternatively spliced 
genes.  Early studies of SR protein splicing regulation indicated that SR proteins enhance 
exon inclusion by binding to enhancing elements in the pre-mRNA, and recruiting core 
components of the splicing machinery, such as the U1 snRNP to the 5’ splice site, and 
U2AF to the 3’ splice site. In contrast, it was determined that hnRNP proteins interact 
with silencing elements to antagonize enhancers, such as the SR proteins. One of the best 
characterized example of this antagonistic regulation is the HIV-1 tat exon 3, where 
hnRNP silencing of splicing can be counteracted by an SR protein binding nearby [57]. 
However, exceptions to this model have been found. For example, SR proteins were 
found to repress splicing of the adenovirus L1 unit when bound to an upstream intron 
sequence, also hnRNP L enhanced exon inclusion when bound downstream of the 5’ss 
[108, 109]. An additional study comparing genes regulated by two SR proteins, ASF/SF2 
and B52, and four hnRNP family members found that both SR and hnRNP could active 
and repress AS events. Also, little overlap was found in regulated AS targets between SR 
and hnRNP family members [74, 116]. These studies suggest that SR proteins can both 
activate and silence exon inclusion in certain contexts, and that antagonistic regulation 
between SR and hnRNP proteins may not be a major mode of regulation.  
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SR proteins were first grouped together based on their protein domain organization, and 
ability to influence splicing. Initially, the ability of multiple SR proteins to enhance 
splicing suggested that SR proteins function as redundant regulators. However, the 
observation that embryonic or cellular lethality when a single SR protein is deleted could 
not be rescued by expression of other SR protein family members, suggested that SR 
proteins were not functionally equivalent [117]. Additionally, evidence that individual SR 
proteins have differences in their ability to regulate alternative splicing was shown. One 
of the earliest examples was that the overexpression of ASF/SF2 and SC35 produced 
different patterns of altered splicing of the adenovirus E1a pre-mRNA, but had a similar 
affect on SV40 early pre-mRNA splicing patterns [118]. These observations suggest that 
individual SR proteins are functionally distinct, and can regulate AS in specific ways. 
In addition to AS, there are many other stages of RNA metabolism that SR proteins have 
a role in regulating. SR proteins have been shown to be involved in the regulation of 
transcription, translation, mRNA export, and mRNA stability. Primary transcripts can be 
initiated at alternative promoters (APR), and there can also be differential termination or 
3’ end processing (APA). Many eukaryotic genes contain multiple promoters that 
determine a different transcription start site and first exon of a transcript. This can affect 
the coding region of the protein, or it can affect regulatory regions in the 5’ untranslated 
region (UTR) [119]. In addition to alternative start of a transcript, there are also changes 
in where a transcript terminates, known as alternative polyadenylation (APA). Like APR, 
APA can change the protein coding region of a transcript, or vary the length and 
composition of a transcript’s 3’ UTR [120]. Changing where a transcript begins and 
terminates has been shown to affect how transcripts are exported, localized, and the 
	   30	  
efficiency of translation (protein expression) [121-123]. SR proteins have been shown to 
associate with components of the transcriptional machinery, including the Pol II CTD, 
and many of the other machineries that are required for these processing events, and may 
play a role in regulating the lengths of transcripts [124].   
 To gain insights into how AS is regulated by the entire family of SR proteins, it is 
important to first identify as many physiological target AS events that are affected by 
each protein. Historically, it has been difficult to identify endogenous AS targets for 
splicing regulators, but recent advances in splicing-sensitive microarrays and RNA-Seq 
allow for the discovery of genome-wide regulated AS events. In addition to changes in 
AS, RNA-Seq also allows for monitoring changes in overall gene expression levels, and 
changes in the first exon starting location (APR), and alternative polyadenylation. Using 
RNA-Seq when SR protein expression is knocked-down, we report here that SR proteins 
regulate a distinct, but overlapping, set of AS events. SR proteins can act as activators 
and silencers of inclusion of many AS events. Additionally, several SR proteins can 
regulate the same event, and in some cases, multiple SR proteins can regulate an AS 
event in opposite ways. We further show that this co-regulation is not redundant, but 
combinatorial. We also show that SR proteins can regulate the overall gene expression of 
transcripts, and can regulate APR and APA, independent of their role in canonical AS 
regulation.  
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2.2 Materials and Methods 
2.2.1 Drosophila S2 cell culture  
D.mel2 cells (GIBCO) were maintained at 25˚C in Drosophila schneider’s media 
(GIBCO # 21720) plus 10% fetal bovine serum (PAA #A15-701). 
2.2.2 SR protein RNAi 
In vitro transcription, RNA purification, and preparation of double-stranded RNA 
(dsRNA) were done as described [74, 116]. The dsRNA is generated from a PCR 
template carrying T7 RNA polymerase promoters on each end. Primers are designed 
carrying the T7 RNA polymerase promoter sequence and ~300-400nt of target sequence. 
For each SR protein two non-overlapping target sequences were chosen to produce two 
targeting dsRNAs for each protein using the primers below: 
Primers used to generate dsRNA (5’ to 3’) 
SC35-S-1 
5-TAATACGACTCACTATAGGGAGGAATGAGCAACGGTGGTGGTGC-3 
SC35-AS-1 
5-TAATACGACTCACTATAGGGAGGAGCGGGCCATCTGTACGCGGA-3 
SC35-S-2 
5-TAATACGACTCACTATAGGGAGGACGCCCCTCTTCGCCCACTCG-3 
SC35-AS-2 
5-TAATACGACTCACTATAGGGAGGACTAGGAGCGACTGCGACTAC-3 
SF2-S-1 
5-TAATACGACTCACTATAGGGAGGAATGGGATCACGCAACGAGTG-3 
SF2-AS-1 
5-TAATACGACTCACTATAGGGAGGACCCACCGTCGCGGCTTCGGT-3 
SF2-S-2 
5-TAATACGACTCACTATAGGGAGGACCGCCAGCCAAGCGCTCGCAGTAC-3 
SF2-AS-2 
5-TAATACGACTCACTATAGGGAGGAGCCACCACCTCCACCGCTGCCG-3 
SRp54-S-1 
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5-TAATACGACTCACTATAGGGAGGAATGGCTGGCGGCAACACCCC-3 
SRp54-AS-1 
5-TAATACGACTCACTATAGGGAGGACTTGAGCATCTCCAGGGCCCGAT-3 
SRp54-S-2 
5-TAATACGACTCACTATAGGGAGGATCACACCGCAGCGAGAAGCA-3 
SRp54-AS-2 
5-TAATACGACTCACTATAGGGAGGACTAGGGCGAGTTGGAGATGT-3 
XL6-S-1 
5-TAATACGACTCACTATAGGGAGGATCCGGAACTCGATCCCGCAG-3 
XL6-AS-1 
5-TAATACGACTCACTATAGGGAGGACTAGTCCCTTGAAACGGATC-3 
XL6-S-2 
5-TAATACGACTCACTATAGGGAGGAGCCGGGCTTCGCCTTCGTGG-3 
XL6-AS-2 
5-TAATACGACTCACTATAGGGAGGAGAGTTGCTTCTGCGTCGCTG-3 
Rbp1-S-1 
5-TAATACGACTCACTATAGGGAGGAATGCCGCGATATAGGGAGTG-3 
Rbp1-AS-1 
5-TAATACGACTCACTATAGGGAGGAAGGGCACGCGTTGCGTCTTC-3 
Rbp1-S-2 
5-TAATACGACTCACTATAGGGAGGAACACGCTGCTGCGGCACCAG-3 
Rbp1-AS-2 
5-TAATACGACTCACTATAGGGAGGATTAGAGTTGCAAGTTGAAGGTTGC-3 
B52-S-1 
5-TAATACGACTCACTATAGGGAGGAATGGTGGGATCTCGAGTGTA-3 
B52-AS-1 
5-TAATACGACTCACTATAGGGAGGAGTTGTAACGACCGCCCCCGC-3 
B52-S-2 
5-TAATACGACTCACTATAGGGAGGACGCTCCCGCTCGCGATCCAACAAA-3 
B52-AS-2 
5-TAATACGACTCACTATAGGGAGGACTAATCGTCCATGCTCTCGT-3 
Rsf1-S-1 
5-TAATACGACTCACTATAGGGAGGAGACTTTGGCCGGCACAGCAT-3 
Rsf1-AS-1 
5-
TAATACGACTCACTATAGGGAGGATTAGAATCGATGGTTTCCCACCGGCGAG
C-3 
Rsf1-S-2 
5-
TAATACGACTCACTATAGGGAGGAATGTCCAGCATGGGTGATCAGCGCGGGA
CA-3 
Rsf1-AS-2 
5-TAATACGACTCACTATAGGGAGGAGCGTCGTCCGCCCCTGTCCA-3 
Rbp1Like-S-1 
5-TAATACGACTCACTATAGGGAGGAATGCCACGCTACCGTGAATGG-3 
Rbp1Like-AS-1 
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5-TAATACGACTCACTATAGGGAGGAGATGCGGGTGCCACAGCAGCG-3 
Rbp1Like-S-2 
5-TAATACGACTCACTATAGGGAGGAGTCGAAATGTCATCAGGCCGT-3 
Rbp1Like-AS-2 
5-TAATACGACTCACTATAGGGAGGACTAATGGCGGTCCCTGGAGTC-3 
 
After PCR template is generated, in vitro transcription was performed using 50ng of PCR 
template, 150 Units T7 RNA polymerase (Invitrogen #18033-019) according to 
manufacture protocol, and incubated overnight at 37˚C. RNA was purified using Qiagen 
RNeasy midi kit (Qiagen #75144).  Purified RNA was annealed by diluting RNA to 
1mg/ml in 10mM Tris-Cl pH 7.5, 100mM NaCl and heating to 95˚C for 5 minutes then 
letting cool to room temperature for 1 hour.  
RNAi knockdowns were performed by seeding 2 X 106 cells per well in a 6-well plate 
and adding 10µg dsRNA. After 48hr of incubation, a second round of 10µg dsRNA was 
added, and incubated an additional 48hr. The cells were harvested and the RNA purified 
using the RNeasy kit following the manufacturer’s protocol (Qiagen #74106) 
For experiments were two SR proteins were knocked-down simultaneously, 10µg of 
targeting dsRNA for each SR protein was added.  
2.2.3 Generation of recombinant SR proteins for rabbit immunization 
SR protein RRM-domains were amplified from cDNAs by PCR and cloned into a 
plasmid that contained an N-terminal pseudomonas endotoxin and a C-terminal 6x 
Histidine tag (pVCH6) using NheI/NotI restriction enzymes. One exception to this 
procedure was Rbp1-Like. Rbp1-Like was cloned using gateway technology (Invitrogen). 
First, Rbp1-Like RRM domain was PCR amplified, then it was cloned into and entry 
vector pDONR221 (Invitrogen) by BP reaction following standard protocols. Next, an 
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LR reaction was performed using pDONR221-Rbp1LikeRRM and pVCH6 that was 
converted to a destination vector. This results in the Rbp1-Like RRM domain inclusion in 
the pVCH6 plasmid.  
Primers used for PCR amplification of SR protein RRM domain  
SC35-RRM-S 
5-GAATTCGCGGCCGCAATGAGCAACGGTGGTGGTGCC-3 
SC35-RRM-AS 
5-GTGATGGCTAGCGTAGCGGGCCATCTGTACGCG-3 
SF2-RRM-S 
5-GAATTCGCGGCCGCAATGGGATCACGCAACGAGTGC-3 
SF2-RRM-AS 
5-GTGATGGCTAGCTACGCGAATGTAGGCAACCTC-3 
SRp54-RRM-S 
5-GAATTCGCGGCCGCAATGGCTGGCGGCAACACCCCG-3 
SRp54-RRM-AS 
5-GTGATGGCTAGCGACGCTTAGATGGCCACCCTT-3 
XL6-RRM-S 
5-GAATTCGCGGCCGCAATGTCGCGCCATCCGAGCGAT-3 
XL6-RRM-AS 
5-GTGATGGCTAGCCACACGGGCTCGGCGCCCGCA-3 
Rbp1-RRM-S 
5-GAATTCGCGGCCGCAATGCCGCGATATAGGGAGTGG-3 
Rbp1-RRM-AS 
5-GTGATGGCTAGCTACGCGAATCCTGGTGCCGCA-3 
B52-RRM-S 
5-GAATTCGCGGCCGCAATGGTGGGATCTCGAGTGTAT-3 
B52-RRM-AS 
5-GTGATGGCTAGCGACCAAGTGGATCCGCCTGCC-3 
Rsf1-RRM-S 
5-GAATTCGCGGCCGCAATGTCCAGCATGGGTGATCAG-3 
Rsf1-RRM-AS 
5-GTGATGGCTAGCGCCAAAGTCGCCGCGTCGTCC-3 
Rbp1Like-RRM-S 
5-GCCAATGAATTCATGCCACGCTACCGTGAATGGGATTTAGC-3 
Rbp1Like-RRM-AS  
5- CGTGTCGAGCTCGCGACCCTCTCGTGAACGGCCTGAT-3 
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Protein expression of the different recombinant proteins in Rosetta BL21(DE3)pLysS 
cells were done following standard procedures (Novagen). Following Lysis of the 
pelleted bacteria in denaturing lysis buffer (50mM Tris-Cl pH 7.5, 1M NaCl, 20 mM 
imidazole-HCL pH 7.5, 0.1% Triton-X, 6M Urea) proteins were purified using a 20 CV 
gradient of imidazole on a 1 mL HiTrap Chelating HP column (GE #17-0408-01) using 
an AKTA purifier 10 (GE Healthcare). The purified recombinant proteins were injected 
into two rabbits, per SR protein, according to standard protocols (Cocalico Biologicals, 
Inc, Reamstown, PA).  After immunization, serum was extracted and SR protein specific 
antibodies were affinity purified. 
2.2.4 Generation of recombinant protein and antibody affinity purification 
Full-length SR proteins were amplified by PCR from cDNAs and cloned into the pET-
30a(+) vector (Novagen) that contains a C-terminal 6x Histidine tag. Restriction enzymes 
NotI/NcoI for B52 and KpnI/NotI for the others were used for cloning. Again, Rbp1-Like 
was cloned using gateway technology (Invitrogen). First, Rbp1-Like was PCR amplified, 
then it was cloned into and entry vector pDONR221 (Invitrogen) by BP reaction 
following standard protocols. Next, an LR reaction was performed using pDONR221-
Rbp1Like and pET-DEST42, which is pET-30a (+) converted to a Gateway destination 
vector. This results in the Rbp1-Like inclusion in the pET-DEST42 plasmid. 
Primers used for PCR amplification of full-length SR proteins  
SC35-FL-S 
5- CAGATCGGTACCATGAGCAACGGTGGTGGTGCC-3 
SC35-FL-AS 
5- ACTCGATGCGGCCGCCTAGGAGCGACTGCGACTACG-3 
SF2-FL-S 
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5- CAGATCGGTACCATGGGATCACGCAACGAGTGC-3 
SF2-FL-AS 
5- ACTCGATGCGGCCGCTTAATAGTTAGAACGTGAGCG-3 
SRp54-FL-S 
5- CAGATCGGTACCATGGCTGGCGGCAACACCCCG-3 
SRp54-FL-AS 
5- ACTCGATGCGGCCGCCTAGGGCGAGTTGGAGATGTC-3 
XL6-FL-S 
5- CAGATCGGTACCATGTCGCGCCATCCGAGCGAT-3 
XL6-FL-AS 
5- ACTCGATGCGGCCGCCTAGTCCCTTGAAACGGATCG-3 
Rbp1-FL-S 
5- CAGATCGGTACCATGCCGCGATATAGGGAGTGG-3 
Rbp1-FL-AS 
5- ACTCGATGCGGCCGCTTAGAGTTGCAAGTTGAAGGT-3 
B52-FL-S 
5- GTCCAGCCATGGATGGTGGGATCTCGAGTGTAT-3 
B52-FL-AS 
5- ACTCGATGCGGCCGCCTAATCGTCCATGCTCTCGTT-3 
Rsf1-FL-S 
5- CAGATCGGTACCATGTCCAGCATGGGTGATCAG-3 
Rsf1-FL-AS 
5- ACTCGATGCGGCCGCTTAGAATCGATGGTTTCCCAC-3 
Rbp1Like-FL-S 
5- GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGCCACGCTACCGTGAA-3 
Rbp1Like-FL-AS  
5- 
GGGGACCACTTTGTACAAGAAAGCTGGGTAATGGCGGTCCCTGGAGTCGGA-3 
 
Protein expression of the different recombinant proteins in Rosetta BL21(DE3)pLysS 
cells were done following standard procedures (Novagen). Following Lysis of the 
pelleted bacteria in native lysis buffer (50mM Tris-Cl pH 7.5, 1M NaCl, 20 mM 
imidazole-HCL pH 7.5, 0.1% Triton-X) proteins were purified using a 20 CV gradient of 
imidazole on a 1 mL HiTrap Chelating HP column (GE #17-0408-01)  using an AKTA 
purifier 10 (GE Healthcare). 
~5mg of purified SR proteins were coupled to CNBr-agarose beads (GE Healthcare #17-
0430-1) by first dialyzing the recombinant proteins 3x 1hr into coupling buffer (50mM 
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sodium borate pH 8.5 and 500mM NaCl). 0.5g of CNBr-agarose beads were activated, 
per sample, by rinsing with cold 100mM HCl for 20 minutes. Next, the beads were 
washed with 200mL of cold 100mM HCl, and then pelleted by centrifugation for 30 
seconds at 750g. The protein sample was brought to 10mL (or more) with coupling 
buffer, and then added to the activated beads for 4 hours at room temperature. The 
remaining reactive groups were blocked by the addition of 1 ml of 1M Ethanolamine pH 
8.0, and incubated an additional 1-hour. Beads were transferred to columns and washed 
3x with buffer A (50mM Sodium Acetate pH 4.0, 500mM NaCl), 3x with buffer B 
(50mM Sodium Borate pH 8.0, 500mM NaCl), and 2x with PBS. The CNBr-agarose 
beads are now bound with recombinant protein. 
The CNBr activated columns were used to affinity purify SR specific antibodies. First, 
the protein-bound beads were mixed with ~50mL of serum from SR protein immunized 
rabbits, and incubated overnight at 4˚C. The serum/bead mixture is added back to the 
column and washed 1x with 10ml wash A (50mM Tris-Cl pH 8.0, 120mM NaCl, 0.5% 
NP-40), 1x with 10ml wash B (50mM Tris-Cl pH 8.0, 1M LiCl, 0.5% NP-40), again with 
10ml wash A, then with 10ml PBS. The antibodies are eluted from the column into a 
fraction collector with 5ml elution buffer (50mM Glycine-Cl pH 2.5, 150 NaCl). 
Fractions were ~500µl and were neutralized with 7.5µl of 2M Tris-base. Fractions were 
analyzed by Bradford assay for protein presences and the most concentrated fractions 
were pooled as affinity purified SR protein antibodies. 
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2.2.5 Verifying antibody specificity and SR protein RNAi knockdown  
After RNAi knockdown of individual SR proteins in S2 cells 10% of the cells were 
recovered added to NuPAGE LDS protein sample buffer (Invitrogen #NP0007). Samples 
were loaded on a NuPAGE 10% Bis-Tris midi gel (Invitrogen #WG1203BOX) and ran 
according to manufacture’s protocol. The proteins were then transferred to a 
nitrocellulose membrane using the iBLOT transfer system (Invitrogen #IB301001). The 
membrane was blocked with 5% milk for 1hr, and then blotted with each SR protein 
affinity purified antibody (described above) at a dilution of 1:5000 for 1hr. The 
membrane was washed 3X 15 minutes with TBST. Next, rabbit secondary antibody 
conjugated with HRP (Invitrogen #G21234) was added at a dilution of 1:5000 for 1hr. 
The membrane was washed again 3x 15 minutes with TBST, then ECL western blotting 
detection agent (GE Life Sciences #RPN2132) was added and visualized with film.  
2.2.6 Illumina next-generation sequence sample library preparation and sequencing 
All sequencing libraries were prepared in collaboration with the Stowers Institute for 
Medical Research Molecular Biology Core facility using Illumina RNA-Seq sample prep 
kits (Illumina) according to manufacture’s protocol. Briefly, polyadenylated RNA was 
purified from 2µg of total RNA using oligo-dT magnetic beads. The resulting RNA was 
fragmented, followed by first and second strand cDNA synthesis primed with random 
hexamers. The cDNA fragment ends were blunted (repaired) and Illumina sequencing 
adapter oligonucleotides were ligated to the ends. cDNA fragments are enriched by PCR 
amplification and size-selected from an agarose gel for a size of ~260bp. The library was 
validated and quantified on an Agilent Technologies 2100 Bioanalyzer using a DNA chip 
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(Agilent DNA-1000 kit). The samples were loaded onto a flow-cell for cluster generation, 
and sequenced using an Illumina Genome Analyzer II or Illumina HiSeq 2000 using 
single-read protocols (Illumina).  
2.2.7 Alternative splicing event analysis (ASEA) 
The ASEA pipeline was created in collaboration with Malcolm Cook and Marco 
Blanchette. Todd Bradley and Malcolm Cook wrote the description of the analysis. 
Models of transcription from Flybase are analyzed to produce an alternative splicing 
event (ASE) catalog for the Drosophila melanogaster genome (v5.22). For each gene in 
the genome, a pairwise comparison of all the gene’s transcript isoforms is made. To 
identify alternative transcript isoforms that vary at the 5’ and 3’ ends, an ASE is declared 
wherever the comparison identifies divergent segments of transcription that are flanked 
on at least one side (5’ or 3’) by convergent transcription. The genomic coordinates of the 
segments unique to each form uniquely identify the event, and are entered into the 
catalog. Furthermore, the AS type (e.g. cassette exon) that characterizes the pattern of 
splicing is assigned based on the structure of transcriptional convergence/divergence, and 
can be used to sort ASEs by common types.  This analysis produces a catalog of all the 
annotated ASEs in Drosophila melanogaster.  
Bowtie is used to perform the alignment of sequence reads, from SR-depleted and control 
samples, to the Drosophila melanogaster (v5.22) genome, and a database of splice-
junctions (36nt on each side of the splice-junction). Bowtie options allow for up to two- 
nucleotide mismatches, and only reads that produce a single alignment are kept. Reads 
that had more than two mismatches and/or aligned multiple times were discarded.  
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Next, for each event in the ASE catalog, the numbers of reads are tabulated that supports 
the inclusive form, exclusive form, both forms (constitutive), and reads that do not 
support either form. Two Fisher Tests are used to compare the tabulated read counts 
occurring in the SR-depleted and control results for each ASE. One is used to test 
significant changes in the inclusive counts, and the other tests for significant changes in 
the exclusive counts. This allows for identification of statistically significantly changed 
ASEs. To determine the magnitude and direction of splicing change PSI (percent spliced 
in) values are calculated. PSI is the ratio of counts of reads aligned to the inclusive region 
to counts of those aligned to either the inclusive or exclusive region. A PSI-switch score 
is computed as the difference between experimental and control PSI scores. A positive 
PSI-switch score indicates a greater presence of the inclusive isoform in the experimental 
sample (inclusion), whereas a negative score indicates greater presence of the exclusive 
isoform (skipping).   Simple ASEs (cassette exon, alt. acceptor, alt. donor, retained-
intron, and mutually exclusive exon) that were changed significantly (p ≤ 0.05), and 
changed by at least 10% (PSI-switch ≥ 0.1) were included for down-stream analysis. In 
addition, the same filter was used on ASEs that differed in their 5’ and 3’ ends. 
2.2.8 RT-PCR validation of affected targets 
cDNA was generated by reverse transcribing ~5µg of the total RNA extracted from the 
control and SR-depleted cells using a mixture of oligo (dT) and random hexamer (N6) 
primers, and Superscript III reverse transcriptase (Invitrogen) according to the 
manufacturer’s protocol. PCR amplification of predicted targets was performed for 25-30 
cycles with primers falling in exons flanking the alternative spliced region.  
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Primers used for PCR of ASEs: 
CG34232_F 
5-TTGCATCGCAGAAACAGAAG-3 
CG34232_R 
5-GTTCAGATGATGGGTTCGCT-3 
CG12090_F 
5-AGTCTTACCTCTGGGGAGCC-3 
CG12090_R 
5-AAGTAGTCCGTGGTGATGGG-3 
CG31638_F 
5-GGGAGTTAGCTGGTGCTGAG-3 
CG31638_R 
5-CTAGTCGCTGTTACCCTCCG-3 
Sfmbt_F 
5-CGAGCAGTCAACGACACAGT-3 
Sfmbt_R 
5-CACCAGCTCCAAGTGAGGTT-3 
Vps35_F 
5-TCGGCAATCGATATCTCCTC-3 
Vps35_R 
5-CTCGCTAGTCCAATGGCTTC-3 
Nfat_F 
5-CGCAGCAGCATTTAATCAGA-3 
Nfat_R 
5-GTTCAGCGGTGTAGTGGGTT-3 
Su(Z)12_F 
5-AGTATGGCCAGAAACGCAAT-3 
Su(Z)12_R 
5-GCCGCTTGTTAAGCACTGTA-3 
Syb_F 
5-TGATCATTCTGGGCGTGATA-3 
Syb_R 
5-TTTGGTCCTTTTCCATTTCG-3 
Dre4_F 
5-GCTCTGATGAGGAATCTGGC-3 
Dre4_R 
5-GTCCCGGCTGTTGTACTTGT-3 
CG12065_F 
5-CAAGGAGACATTCGTCCGAT-3 
CG12065_R 
5-GTCGACCTTTTGGAATGTGC-3 
DppIII_F 
5-GCACTTTTGTCGGCATTTCT-3 
DppIII_R 
5-CTCGGTGAGATTCTCGAAGG-3 
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Pep_F 
5-GTTCGGATCGGAGCGTAATA-3 
Pep_R 
5-CGGATTTCCGTTGACCTTTA-3 
 
PCR products were analyzed on an Agilent Technologies 2100 Bioanalyzer, using a 
DNA chip (Agilent DNA-1000 kit) according to manufacture’s instructions.  
2.2.9 Identifying changes in overall transcript abundance 
RNA-Seq reads from control and SR-depleted experiments were processed and aligned, 
simultaneously, to the genome and splice-junction database as described previously. For 
each condition, the mRNA RPKM (reads per kilobase of million mapped reads) was 
computed for each gene to measure relative expression. To detect differentially expressed 
genes in SR-depleted samples, the bioconductor edgeR package was used. EdgeR 
provides methods for the statistical analysis of count data from comparative experiments, 
using RNA-Seq data. Over-dispersed Poisson count models are used to distinguish true 
biological variation from technical variation. This allows for the identification of 
significant differentially expressed genes in the SR-depleted samples. We limited our 
analysis to genes that were in the top three quartiles of expression (top 75%) based on 
their RPKM values, and only considered significantly changed genes that varied ≥ 2-fold.  
2.3 Results 
2.3.1 Identification of genome-wide SR-dependent alternative splicing events 
To identify the SR protein network regulating AS, we reduced the protein levels of SR 
proteins SC35, SF2, SRp54, XL6, Rbp1, B52, Rsf1, and Rbp1-like using RNAi. Each 
protein was knocked-down, in duplicate, using two non-overlapping dsRNAs (Figure  
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Figure 2.1: Experimental strategy for identification of SR protein regulated AS 
events. Total RNA was extracted from Drosophila S2 cells treated with two non-
overlapping SR protein-targeting dsRNAs or control nontargeting dsRNAs. Next, RNA-
Seq libraries were prepared, and subjected to Illumina next-generation sequencing. The 
resulting sequence reads were aligned, simultaneously, to the genome and a splice-
junction database. Then, using a catalog of ASEs, the aligned tags were assigned to the 
inclusive or exclusive isoforms. A student’s t-test was performed to determine ASEs that 
significantly changed in an SR protein knock-down compared to control, and a tabulation 
of reads within each isoform produced PSI and PSI-switch scores to quantify the splicing 
changes.  
 
2.1). To assay protein levels of specific SR proteins, antibodies were produced against the 
RRM-domain of each individual SR protein in rabbits, and western-blots were performed 
on all samples (Figure 2.2). From this analysis, we were able to confirm that each 
antibody specifically recognized each individual SR protein with no cross-reactivity with 
other members of the family. Additionally, all SR proteins levels were reduced to less 
than 10% of their endogenous levels in Drosophila melanogaster S2 cells. Individual SR 
proteins were reduced specifically, with no appreciable changes in other SR protein 
family members (Figure 2.2). One exception was the previously identified Rbp1-like up-
regulation when Rbp1 expression is reduced [125]. We next performed RNA-Seq on 
RNA isolated from control and SR RNAi-treated cells to detect altered splicing events in 
an unbiased fashion (Figure 2.1). We generated ~23-40 million sequence reads per 
sample that were aligned simultaneously to the Drosophila melanogaster genome 
(v5.22), and a splice junction database containing 36 bp on each side of the exon-exon 
junction, using Bowtie. This resulted in the unique alignment of 66.4% – 91.1% of the 
reads to the genome or splice junctions (Figure 2.3). Using a catalog of all annotated AS 
events in Drosophila melanogaster (genome version 5.22) aligned reads were assigned to  
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Figure 2.2: RNAi of the eight members of the Drosophila SR protein family in 
Drosophila S2 cells. Western-blot analysis demonstrating specific depletion of individual 
SR proteins in Drosophila melanogaster S2 cells, in duplicate, as complared with cells 
treated with a non-specific dsRNA. Tubulin was used as a loading control. 
 
the inclusive, exclusive, and constitutive isoforms for each alternative splicing event 
(ASE) in the catalog, and tabulated (Figure 2.1). Reads that aligned to the ASE region, 
but did not support any of the known forms were grouped separately, and excluded from 
the further analysis. These reads may support previously unidentified transcript isoforms. 
This was done independently for reads for each SR protein knock-down and control 
samples. The ratio of the counts of reads that aligned to the inclusive isoform to counts of 
those aligned to either the inclusive or exclusive isoforms are computed for each ASE. 
This is referred to as the percent spliced in (PSI) score (Figure 2.1). The change in PSI 
scores between the experimental and control samples are calculated as the PSI-switch 
score (∆PSI). This score indicates the direction (more inclusion, less inclusion), and the  
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Figure 2.3: RNA-Seq of RNA extracted from control and SR-depleted S2 cells. Total 
number of sequence reads from each sample, and the total number of reads that aligned to 
the Drosophila melanogaster genome and splice junction database.  
 
magnitude of splicing change observed when an individual SR protein is reduced. To 
evaluate if an ASE is significantly changed upon reduction of an individual SR protein, a 
fisher’s exact test is used to compare the tabulated read counts occurring in the control 
and SR protein knock-down sample. We used a stringent criterion of, p ≤ 0.05 and a ∆PSI 
≥ 0.1, this identifies statistically significant AS changes, which change in magnitude by at 
least 10%.  
To simplify our analysis, we focused on the five simplest types of AS (cassette exons, 
competing donor or acceptor sites, mutually exclusive exons, and intron-retention). Using 
our criterion, we identified 561 altered simple AS events upon SR protein depletion, 
representing 405 genes. This represents more than 10% of simple AS events that can be 
reliably detected in S2-cells (5,472 events). Individually, SR proteins regulate different 
numbers of events (Figure 2.4A). B52 regulates the largest number of AS events (253) 
and Rbp1 the smallest (24). Previous studies of SR proteins focused on their regulation of 
cassette exons or competing 5’ and 3’ ss. To test if SR proteins are important for only one 
or a few types of simple AS, we subdivided the affected events into each type of simple 
AS. SR proteins were found to regulate all types of simple AS events, and affect different 
types of simple ASEs in similar proportions (Figure 2.4B).  
SR proteins have previously been shown to be essential for proper tissue development, 
and sex determination in Drosophila melanogaster [50, 61, 126]. Gene ontology (GO)  
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Figure 2.4: SR proteins regulate all types of simple AS events. (A) Total number of 
AS events regulated by individual SR proteins separated by causing more inclusion (inc.) 
or exclusion (exc.) of the alternative region. Number of events are further divided into the 
five simple AS types. (B) Pie charts of the distribution of simple AS types differentially 
regulated by individual SR proteins detected by RNA-Seq. Colors represent the different 
simple AS types that were detected, and the transcriptome is the distribution of simple 
AS events for the expressed transcriptome.  
 
analysis of SR regulated targets using TopGO (using the top 40 nodes) revealed 
overrepresented terms corresponding to cell growth (cell growth, growth, and cell 
proliferation), cellular signaling (regulation of signaling, cell communication), tissue and 
organ generation (system development, tissue and organ development), and neuronal 
processes (generation of neurons, behavior, and neuron differentiation) (Figure 2.5). 
Thus, SR proteins regulate targets important in a broad range of physiological processes.  
2.3.2 SR proteins can function as activators and repressors of splicing events 
Previous studies have suggested that SR proteins bind to ESEs in the pre-mRNA, and 
function as general activators of exon definition. To investigate whether SR proteins 
generally activate or repress AS events, we determined the number of AS events that 
showed increased inclusion or exclusion when an individual SR protein was depleted. We 
found that all SR proteins can function as, both, alternative splicing event activators and 
alternative splicing event silencers (Figure 2.6A and B). Surprisingly, we found that SR 
proteins are important for the repression of more than half of their regulated events 
(58.3% for Rbp1 to 71.4% for Rbp1-like events), with the exception of SRp54 and XL6, 
which are important for the activation of 54.8% and 77.7% of their events, respectively 
(Figure 2.6A). In order to determine if SR proteins preferentially activate or repress a  
	   50	  
 
	   51	  
Figure 2.5: Gene ontology analysis of SR regulated genes. Significantly enriched GO-
terms of genes regulated by SR proteins at the level of AS, using TopGO. Terms are 
listed in descending order of p.value as determined by a fisher-test. Only the top 40 nodes 
are displayed.   
 
specific AS type, we separated the included or excluded events by AS type (Figure 2.7 A-
E).  SR proteins tend to activate more cassette exons than other types of AS, with the 
exception of B52, which represses 53.1% of cassette exon events (Figure 2.7A).   
Additionally, SR proteins are important for the repression of most intron-retention 
splicing events, except for XL6, which activates 84.4% of its regulated intron-retention 
events (Figure 2.7D). Since SR proteins affect more intron-retention events than any 
other form of AS, these events contribute significantly to the overall repression of AS 
observed (Figure 2.4B). The observation of cassette exon activation, and repression of 
intron-retention events, are consistent with reports that SR proteins activate exon 
recognition [54].  However, there are many examples where SR proteins silence inclusion 
of AS regions, and to different extents.  
Semi-quantitative RT-PCR of predicted targets demonstrates that multiple SR proteins 
can act as activators (Su(Z)12 and CG12090) or repressors (Pep and Syb) of the same 
splicing event (Figure 2.8). Surprisingly, we also identified events where some SR 
proteins activate inclusion, and others act to repress inclusion. Such as the enhanced 
skipping of a cassette exon in the Dre4 transcript when XL6 or Rsf1 are depleted, and the 
increased inclusion of the same exon when SC35 or B52 are depleted (Figure 2.8). This 
observation of antagonistic regulation suggests that all SR protein AS regulation is not 
completely redundant, but different SR proteins can regulate an alternatively spliced  
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Figure 2.6: Genome-wide analysis of SR-dependent AS events. (A) Number of simple 
AS events regulated by each SR protein. Bars are divided to display the proportion of 
events that are less included upon depletion (SR-activated, red), or more included upon 
depletion (SR-repressed, dark gray). (B) Heatmap shows hierarchical clustering of PSI-
switch scores for SR-regulated AS events.  
 
region differently. We conclude that all 8 SR proteins can act both as repressors and 
activators of AS events. Additionally, multiple SR proteins can regulate the same event, 
and in some cases multiple SR proteins can regulate an AS event antagonistically.  
2.3.3 SR proteins collaborate to regulate a majority of AS events 
Many alternative splicing events have been demonstrated to be regulated by multiple 
RNA splicing factors in a combinatorial manner [116]. For example, the SR proteins 
Rbp1 and SF2 cooperate with Tra and Tra-2 to regulate the Drosophila AS event in 
Doublesex [61].  Additionally, cooperative regulation, genome-wide, of AS by another 
well-characterized splicing regulator family, hnRNPs, has been demonstrated in 
Drosophila and mammals [74, 112].   Hierarchical clustering across SR protein regulated 
AS events demonstrates that SR protein proteins co-regulate many of the same targets 
(Figure 2.6B).  We found that while individual SR proteins can regulate unique AS 
events, a majority of events are regulated by more than one SR protein (Figure 2.9A). 
One notable exception is B52, which shares only 36% of its targets with other SR protein 
family members.  To determine if SR proteins are acting in concert or antagonistically, 
we noted the direction of change for each co-regulated event, and clustered them 
according to similarity (Figure 2.9B).  Interestingly, a vast majority of co-regulated 
events are affected in the same direction (greater than 87.7% in every case), and very few  
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Figure 2.7: Proportion of events that are less included upon depletion (SR-activated, 
red), or more included upon depletion (SR-repressed, dark gray) by AS type (A-E). 
 
events are regulated antagonistically. Also, while individual events can be regulated by 
specific sets of SR proteins, there are no distinct pairwise relationships between 
individual SR protein family members (Figure 2.9B).  
Rsf1 (repressor of splicing 1) has an RRM domain that shares 54%-58% sequence 
identity with other SR proteins, but has a C-terminal domain that is rich in glycine, 
arginine, and serine (GRS-domain). Previous studies have demonstrated that Rsf1 acts as 
an antagonist of other SR proteins for splice site selection through protein interactions 
within its GRS-domain [127]. Surprisingly, we found that Rsf1 co-regulates 81.4% of its 
events with other SR proteins, and 97.9% of those events are regulated in the same 
direction (Figure 2.9A and B). Therefore, Rsf1 acts in concert with the other SR protein 
family members in most of the identified co-regulated AS events, and is not a global 
repressor of AS through SR protein competition.  
The extensive overlap of regulated AS transcripts raises the possibility that SR proteins 
may redundantly regulate specific AS events. Another possibility is that the SR proteins 
may regulate AS events using a combinatorial mode of regulation. To provide insights 
into the mechanism of SR protein co-regulation, we reduced the expression of two SR 
proteins simultaneously (SC35:B52 and XL6:B52) in S2 cells. We confirmed that both 
SR protein expression levels were reduced by western-blot (Figure 2.10A). We next 
isolated the RNA and prepared libraries for RNA-Seq (described above). After  
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Figure 2.8: Differentially regulated events detected by RT-PCR. RT-PCR validation 
of SR-regulated AS events (p ≤ 0.05; ∆PSI ≥ 0.1). Events separated into activator, 
repressor, or antagonistic. Red color stars indicate activator and gray stars indicate 
repressor. 
 
sequencing, we received ~70-105 million reads that aligned to either the Drosophila 
genome (v5.22), or our splice junction database at ~72-77% (Figure 2.3). Next, we 
identified changes in AS between control and simultaneous SR RNAi samples, as 
described previously for individual RNAi samples. In addition to the regulated AS events 
identified when only an individual SR protein is reduced, 205 and 195 new AS event 
changes were detected in the SC35:B52 (395 regulated AS events) and XL6:B52 (347 
regulated AS events) samples, respectively (Figure 2.10B). The identification of so many 
new events suggested that SR proteins are regulating AS in a combinatorial fashion, as 
well as the potential identification of redundantly regulated events.  Also, we noticed that 
the overall magnitude of AS changes were greater for most of the events when two SR 
protein levels are reduced (Figure 2.10B). To examine this further, we compared the PSI- 
switch scores of the 23 co-regulated AS events between SC35 and B52, and the 26 co-
regulated AS events between XL6 and B52 to determine if there was an increase in the 
magnitude of splicing change when both SR proteins were knocked-down (Figure 
2.10C). In 14 of the 23 events co-regulated by SC35 and B52, there was an increase in 
the magnitude of splicing change (PSI switch score) when both SR proteins were 
knocked down simultaneously.  The same was observed for 12 out of the 26 events 
regulated by XL6 and B52 (Figure 2.10C).  This combinatorial regulation can be further 
demonstrated by semi-quantitative RT-PCR (Figure 2.11). The AS cassette exon in  
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Figure 2.9: Multiple SR proteins co-regulate AS events. (A) Proportion of AS events 
that are uniquely (dark gray bar) or co-regulated by one or more other SR protein family 
member (red bar). (B) Heatmap of co-regulated events divided by events that have 
increased inclusion (yellow) and increased exclusion (blue) when a SR protein is 
depleted. 
 
Su(Z)12 exhibits less inclusion when either SC35 or B52 protein levels are reduced, and a 
further decrease in inclusion is observed when both protein levels are reduced at the same 
time (Figure 2.11). Similarly, when XL6 and B52 are acting as a repressor of the cassette 
exon in CG31638, an increase in the magnitude of repression is observed when both 
proteins are knocked-down simultaneously (Figure 2.11).  Surprisingly, this effect is even 
observed when the two SR proteins have antagonistic functions. XL6 acts as an activator, 
and B52 acts as a repressor, of the cassette exon in the Dre4 transcript. When both XL6 
and B52 are knocked-down together, the result is a splicing change that is near wild-type 
levels (Figure 2.11).  In effect, the opposing regulation by these two SR proteins cancels 
each other out. These results indicate that the SR proteins co-regulate a majority of their 
AS targets, and this co-regulation is not redundant, but combinatorial.  
2.3.4 SR proteins regulate promoter selection and 3’ end processing of target 
transcripts 
Many eukaryotic genes contain multiple promoters that determine a different start site 
and first exon of a transcript. Alternative promoter usage allows tissue-specific regulation 
of gene expression, and allows the target transcripts expression to be modulated at the 
transcriptional level. Alternative promoter usage can change the coding sequences of a  
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Figure 2.10: Combinatorial regulation of AS by the SR proteins. (A) Western-blot 
analysis demonstrating that individual and pair-wise SR protein expression could be 
reduced, specifically, in S2 cells. aWestern-blot analysis demonstrating (B) Heatmap 
shows hierarchical clustering of PSI-switch values for AS events changed with the 
depletion of SR proteins individually or pair-wise. (C) Heatmap shows hierarchical 
clustering of PSI-switch values for AS events co-regulated by SC35 and B52 (left panel) 
or XL6 and B52 (right panel) and the magnitude of splicing change when the pairs are 
simultaneously depleted. 
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protein, and produce functionally distinct protein isoforms. It can also change the 
regulatory regions in the 5’ UTR that can affect protein expression levels and stability.  
Using our alternative splicing event analysis from the mRNA-Seq data, we can monitor 
changes in alternative first exon usage. Surprisingly, SR proteins affect the frequency of 
usage of many alternative first exons (Figure 2.12A). Rbp1L regulates the usage of the 
fewest (71 first exons in 41 genes), and SRp54 regulates the most (278 first exons in 133 
genes) first exons using our stringent AS filter (p ≤ 0.05; ∆PSI ≥ 0.1). For example, when 
XL6 or B52 are reduced there is decreased usage of the distal promoter of the 
transcription factor Nfat, similarly, we found that there is increased usage of the two 
proximal promoters of the transporter gene Indy (Figure 2.12B). Currently, it is not clear 
how, mechanistically, SR proteins control promoter selection. A plausible mechanism 
could originate from the observation that SR proteins have been shown to associate with 
components of the transcriptional machinery, including the Pol II CTD. These protein-
protein interactions could mediate the selection of the first exon of a transcript, 
independent of the SR protein’s role in AS. 
In addition to regulating the location of transcript initiation, SR proteins can also regulate 
where a transcript terminates, or alternative 3’ processing. Recent studies have 
demonstrated a dynamic interplay between the cleavage/polyadenylation machineries and 
splicing regulators, and this results in altered protein products and transcript regulation. 
In some cases the alternative polyadenylation sites are located within the exons and 
introns in the protein-coding regions, termed coding region alternative polyadenylation 
(CR-APA), resulting in the production of different protein isoforms. We observed 
significant changes in the use of alternative poly (A) sites when SR proteins were  
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Figure 2.11: RT-PCR demonstrates combinatorial splicing control of specific SR 
targets.  RT-PCR of co-regulated AS events affect in the same direction (cooperative; 
Su(z)12 and CG31638) or opposing direction (antagonistic; Dre4) in conjunction with the 
simultaneous knock-down. 
 
depleted (Figure 2.13A). Again, using our stringent filter (p ≥ 0.05; ∆PSI ≥ 0.1), XL6 
regulates the largest number of CR-APA events (53 events), and Rbp1 regulates the 
smallest number (6 events).   The number of CR-APA events regulated by individual SR 
proteins are consistent with the number of other types of AS regulated by the SR proteins, 
indicating that this is a significant mechanism of regulation by the SR protein family. 
With the exception of SC35, the majority of regulated events shift to use of the proximal 
poly (A) site when SR protein level is reduced (Figure 2.13A). This means that in a 
majority of cases the SR proteins ensure that the longer transcript is produced. This could 
ensure inclusion of important regulatory sequences, and production of a functional 
protein. 
An example of this type of regulation is found in the Pnuts gene, where two poly (A) 
sites are used to encode a transcription regulator (Figure 2.13B). The use of the proximal 
poly (A) site results in a transcript that is over 2000 nucleotides shorter in length, and a 
protein that is half as large than when the distal poly (A) site is used. Reduction of XL6 
or B52 results in a decrease in use of the proximal, and an increase in use of the distal 
poly (A) site of this transcript (Figure 2.13B). Use of the proximal poly (A) site of 
CG34439 results in a 74 amino acid protein compared to a 123 amino acid long protein 
when the distal site is used (Figure 2.13B). There is a reduction in use of the distal site  
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Figure 2.12: SR proteins regulate transcript start sites. (A) Number of transcripts with 
an SR regulated alternative 5’ end, and total number of SR regulated first exons. (B) 
Examples of transcripts with altered 5’ starts when SR proteins are depleted. Alternative 
first exons are denoted with red boxes, and the sequence tag density from RNA-Seq for 
control (black), XL6 (dark gray), and B52 (light gray) are above the gene model in the 
black box. 
 
when XL6 or B52 protein levels are knocked-down, indicating that those two SR proteins 
are important for ensuring production of the longer protein isoform.  
In addition to APA sites that occur in the protein-coding region, there are APA sites 
located in the 3’ UTR that do not change the protein sequence, but can affect the 
expression of the protein, termed untranslated region alternative polyadenylation (UTR-
APA). For example, extending the 3’ UTR can introduce microRNA (miRNA) binding 
sites, or other regulatory sequences such as AU-rich elements (AREs) and RNA 
localization signals. SR proteins can also affect the use of poly (A) sites within the 3’ 
UTR (UTR-APA) (Figure 2.14). Rbp1 regulates the smallest number (4 events) and XL6 
regulates the largest (65 events) (Figure 2.14A). Similar to CR-APA, there is a shift to 
use of the proximal poly (A) site in a majority of cases when individual SR proteins are 
depleted, indicating a global role for SR proteins in ensuring that longer transcripts are 
produced (Figure 2.14A). Two notable exceptions are B52 and SC35, which in both CR-
APA and UTR-APA, many more events result in use of the distal poly (A) site, indicating 
these SR proteins may promote production of shorter transcripts.  Notable examples 
include Fab1, a kinase that has been characterized as important for controlling cell 
growth and organ size (Figure 2.14B). When B52 protein levels are reduced there is a 
significant increase in use of the distal poly (A) site. Therefore, B52 is important to  
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Figure 2.13: SR proteins regulate alternative polyadenylation that changes the 
protein coding sequence. (A) Total number of transcripts with APA within the coding 
region divided in shifts to the proximal (blue bar) or distal (red bar) polyadenylation site 
when an individual SR protein is depleted. (B) Examples of transcripts with APA when 
SR proteins are depleted. Alternative regions and poly(A) sites are denoted with red 
boxes, and the skinny portion denotes the 3’ UTR. The sequence tag density from RNA-
Seq for control (black), XL6 (dark gray), and B52 (light gray) are above the gene model 
in the black box. 
 
promote the use of the shorter 3’UTR that excludes 1000 nucleotides of potential 
regulatory sequences.  Similarly, CG6700 is a gene that is highly expressed in the 
Drosophila brain. When XL6 is reduced there is a switch to use of the proximal poly (A) 
site (Figure 2.14B). Therefore, XL6 is responsible for maintaining the long 3’ UTR of 
this transcript. The differences in proximal or distal poly (A) site regulation by the SR 
proteins could be a result of cell or tissue specific expression regulation.  
One striking difference between CR-APA and UTR-APA is the mechanism that may be 
used by SR proteins to regulate APA site choice. CR-APA could be the result of 
differential selection of splice sites, by the SR proteins, that include or remove poly (A) 
selection regulatory sequences from the transcript, and ultimately change where the 
transcript is cleaved and polyadenylated. However, UTR-APA involves differential 
selection of poly (A) sites, independent of splice site selection (Figure 2.14B). Many 
RNA-binding proteins have been implicated in UTR-APA control by enhancing or 
antagonizing the action of the formation of the 3’ processing complex, but SR proteins 
have only been implicated in CR-APA [128]. These results extend regulation of UTR-
APA to the SR protein family, and also suggest SR protein interaction with the 3’ 
processing machineries.  
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Figure 2.14: SR proteins regulate alternative polyadenylation in the 3’ UTR 
independent of AS. (A) Total number of transcripts with APA within the 3’ UTR 
divided in shifts to the proximal (blue bar) or distal (red bar) polyadenylation site when 
an individual SR protein is depleted. (B) Examples of transcripts with APA when SR 
proteins are depleted. Alternative polyadenylation sites are denoted by p(A), and the 
skinny portion denotes the 3’ UTR. The sequence tag density from RNA-Seq for control 
(black), XL6 (dark gray), and B52 (light gray) are above the gene model in the black box. 
 
2.3.5 SR proteins are required for maintaining the cellular transcriptional profile 
In addition to regulating transcript length and sequence composition, SR proteins can 
modulate gene expression levels at other stages of RNA metabolism, such as mRNA 
export, stability, and translation. SR proteins have also been shown to affect 
transcriptional elongation, and associate with sites of active chromatin [72, 129].  To 
identify transcripts that had significant changes in their levels of expression when an 
individual SR protein is absent, we computed the number of uniquely mapped reads per 
kilobase of exon, to normalize for length of transcripts, per million mapped reads 
(RPKM), for each gene in the SR protein RNAi RNA-Seq samples. Next, we used the 
edgeR package to calculate significant differential gene expression levels between control 
and SR-depleted RNA-Seq samples.  Surprisingly, there are a large number of genes 
whose expression is significantly changed (≥ 2 Fold-Change) when an individual SR 
protein is depleted (Figure 2.15A). 539 genes have altered expression levels when XL6 is 
depleted (the lowest), and 1,230 genes when B52 is depleted (the highest). This 
represents between 6.1% and 13.8% of reliably detected genes expressed in S2 cells 
(8,891 genes). In total, SR proteins regulate the expression of 2,283 (1,661 up-regulated 
and 722 down-regulated) genes. This means that SR proteins can regulate the expression 
of 25.7% of the expressed genes in S2 cells, a striking number. Expression levels are 
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changed in both directions (increased and decreased), but a majority of targets are up-
regulated when an individual SR protein is reduced (Figure 2.15A).  
Hierarchal clustering of the affected genes in each experiment reveals that, similar to 
splicing regulation, SR proteins affect the gene expression of a distinct and similar set of 
genes (Figure 2.15B). GO analysis of significantly enriched GO terms, by TopGO (Top 
20 nodes), revealed that transcripts that increase in expression level in the absence of SR 
proteins play key roles in cell growth and signaling, and transcripts whose expression 
level is decreased are important for reacting to external stimuli and tissue development 
(Figure 2.16). Therefore, altering SR protein levels can assist the cell in the rapid 
response to different cellular cues.  
The number of genes with differential expression upon SR protein knock-down exceeds 
the total number of genes identified with changes in simple AS events. This indicates that 
the SR proteins may influence the expression of their targets independent of their role in 
AS. To investigate if SR protein AS regulation plays a major role in controlling overall 
transcript levels, we compared the previously identified regulated AS events, and 
determined if there were significant changes in gene expression levels. In a vast majority 
of cases (> 62.5% for Rbp1 and > 80% for all other SR proteins) genes affected at the 
level of AS had no significant changes in transcript abundance (Figure 2.17).  
This indicates that regulation of transcript expression by the SR proteins is downstream 
of direct AS targets, or is independently regulated by a mechanism other than AS. GO 
analysis of AS regulated targets revealed genes involved in cell signaling and 
development. This could mean that by altering the splicing of a transcriptional or signal- 
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Figure 2.15: SR proteins regulate RNA transcript levels. (A) Total number of genes 
with differential expression in each SR protein knock-down experiment (increased 
expression, red; decreased expression, dark gray). (B) Heatmap showing hierarchical 
clustering of calculated fold-change (log2) values for genes with altered transcript levels 
when an SR protein is depleted. 
 
transduction pathway regulator could contribute to widespread changes in downstream 
gene expression. Indeed, SR proteins regulate the AS of key transcription factors 
(Su(z)12, Iswif, Hsf, Skd) identified by our study. Alternatively, SR proteins may regulate 
gene expression of targets by directly affecting their transcription and/or stability. Either 
way, this provides a sensitive and rapid mechanism to regulate an organism’s gene 
expression profile.  
2.4 Discussion 
In this chapter, we identified global targets of AS regulation for each member of the SR 
protein family in Drosophila. SR proteins share a similar protein-domain structure and 
organization, and since multiple members could complement splicing-deficient S100 
extract, SR proteins were thought to be functionally redundant [130]. The observations 
that (i) when deletion of an individual SR protein resulted in embryonic lethality and (ii) 
that the phenotype could not be rescued by over-expression of another SR protein family 
member demonstrated that SR proteins had specific functions and were not entirely 
redundant.  More recently, it was discovered that individual SR proteins have distinct 
affects on AS outcomes. While many members of the SR protein family have been 
implicated in AS regulation, there has never been a comprehensive study to determine if 
all SR proteins regulate AS and how this regulation is achieved. Many of the previous  
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Figure 2.16: Over-represented GO-terms in SR protein gene expression regulated 
targets. GO-analysis of SR regulated genes that change greater than 2-fold in expression 
when an SR protein is depleted. Enriched GO-terms determined using TopGO. 
 
studies on SR protein AS regulation used in vitro systems, or were based on single gene 
models. There has never been a systematic, genome-wide, analysis of AS for a majority 
of the SR protein family members. Recent advances in the ability to rapidly characterize 
AS have allowed for a more comprehensive analysis of AS. It is now possible to use 
RNA sequencing to identify genome-wide, endogenous, AS events regulated by 
individual SR proteins. A previous study, utilizing splicing-sensitive microarrays 
profiling genome-wide AS events regulated by Drosophila SR proteins, SF2 and B52, 
revealed that they shared a remarkable number of targets. Furthermore, the study pointed 
out that in addition to overlapping targets, SF2 and B52 individually regulate many more 
unique AS events [116]. This suggested that SR proteins could have overlapping 
functions, but also have discrete roles in AS regulation. Here we extend this observation 
of AS co-regulation to the entire family of SR proteins. Using RNA-Seq, we identified 
561 simple AS events regulated by individual SR proteins, and reveal that while 
individual SR proteins can regulate unique targets, a majority of SR regulated AS events 
are controlled by multiple SR protein family members. We also noted the direction of the 
splicing change, and found that all SR proteins can function as alternative splicing event 
activators and silencers. In addition, we found that SR proteins act in concert (regulation 
is in the same direction) to regulate overlapping targets a vast majority of the time, but 
there are a few AS events that are regulated antagonistically by multiple SR proteins.  
Although, we observed no pair-wise SR protein patterns of regulation, it would be  
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Figure 2.17: SR protein regulation of gene expression is independent of AS 
regulation. Heatmaps comparing identified AS regulated events (left heatmap) and their 
corresponding gene expression changes (right heatmap). 
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interesting to determine features of unique and co-regulated SR protein targets that would 
explain why some AS events are only regulated by one member of the SR protein family.  
The observation of cooperative regulation of AS has been demonstrated for the hnRNP 
family of splicing regulators, in both Drosophila and mammals [74, 112]. However, the 
mechanism of the cooperative regulation has not been uncovered. To explore if the SR 
proteins co-regulate AS in a combinatorial manner we depleted two SR proteins, 
simultaneously. We showed that the observed splicing change increased in magnitude 
when two SR proteins were knocked-down together for a large proportion of co-regulated 
targets. Surprisingly, this effect is even observed on AS events that are regulated 
antagonistically. This observation reveals insights governing the co-regulation of AS by 
the SR proteins, and shows that SR protein co-regulation is achieved by combinatorial 
regulation.  
In addition to AS of the same primary transcript, different mRNA isoforms can be 
initiated at alternative promoters, and by differential termination/processing of the 3’ end. 
We found that SR proteins affect the frequency of usage of many alternative first exons, 
and regulate the 3’ end of a variety of transcripts. In both cases this regulation can occur 
independent of the SR protein’s role in splice site selection. Recent studies have 
demonstrated a dynamic interplay between splicing regulators, the 
cleavage/polyadenylation machineries, and components of polymerase II [120]. The 
observation that SR proteins can regulate alternative promoters, and alternative 
polyadenylation, expand SR protein interaction beyond the spliceosome.  One striking 
difference between canonical AS changes, and differences in a transcript’s start and end, 
is that many changes at the beginning and end of a transcript do not change the protein 
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coding sequence. Rather, it modifies the 5’ and 3’ UTR that is used for regulation of 
downstream RNA processing events, such as RNA localization and translation [119, 121, 
122]. SR proteins have been implicated in the regulation of many of these downstream 
RNA processing events. Perhaps one mechanism of this regulation is through interaction 
with the transcription and polyadenylation machineries to regulate the length of a 
transcripts 5’ and 3’ UTR. It would also be interesting to see if translation or RNA 
localization of these transcripts is affected upon SR protein depletion. On the contrary, it 
would be interesting to determine if components of the 5’ and 3’ processing machineries 
can influence SR protein function in AS.  
Mounting evidence suggests that transcription and AS are coupled to one another. The 
CTD of Pol II has been found to be associated with various RNA processing factors, 
including SR proteins [124]. In addition, SR proteins have been shown to associate with 
active chromatin, and affect transcriptional elongation [72]. This suggests that SR 
proteins may have an early function in gene expression regulation, possibly upstream of 
AS regulation. Indeed, there are a large number of genes whose expression is changed 
when an individual SR protein is depleted. Similar to AS regulation, SR proteins affect 
the expression of a very similar, overlapping, set of targets. We also found that most AS 
targets did not have changes in gene expression, and the number of genes with 
differential expression exceeds the total number of genes with changes in AS. This 
indicates that SR proteins may influence the expression of their targets independent or 
downstream of their role in AS regulation. While we observe SR protein regulation of the 
AS of transcriptional regulators, further studies will need to be done to elucidate if gene 
expression regulation occurs downstream of the AS decision. Regardless, our study 
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reveals a large number of genes whose expression relies on SR protein levels. This may 
be a novel mechanism for an organism to regulate its gene expression profile, rapidly, by 
modulating the expression of one or more SR proteins.  
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Chapter III: SR Protein Domain Contribution to Alternative Splicing 
Regulation 
3.1 Introduction 
SR proteins are defined by their ability to promote constitutive and alternative splicing, 
but are also grouped based on similar protein domain architecture (Figure 3.1). SR 
proteins consist of one or two N-terminal RNA recognition motifs (RRM) and a C-
terminal domain enriched in arginine and serine (RS-domain). Typically, it has been 
thought that SR proteins bind pre-mRNA via their RRM domains, and their RS-domains 
function in protein-protein interactions with key components of the basal splicing 
machinery [131]. Using yeast two-hybrid assays, ASF/SF2 was shown to interact with the 
U1 and U2AF snRNPs to promote recruitment of these complexes to splice sites. This 
interaction required the RS-domains of each protein [56, 132]. One drawback of these in 
vitro assays is that it has yet to be demonstrated that these protein-protein interactions 
occur in a functional spliceosome.  
SR proteins have also been reported to promote splicing through RS-domain:pre-mRNA 
interactions. SR protein RS-domains bound to ESEs strengthened base-pairing of U5 and 
U6 snRNAs through RS-domain contact with the branch-point, and promote splicing 
[133]. On the other hand, the addition of free RS-domain to nuclear extract can rescue the 
splicing of a doublesex splicing substrate, arguing that splicing can be accomplished 
without a pre-mRNA binding domain [134]. Additionally, it has been shown that 
ASF/SF2 can interact with U1-70K snRNP through RRM-domain interactions in early 
spliceosome assembly, indicating that the RRM-domain can also contribute to protein- 
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Figure 3.1: SR protein domain organization. The eight identified SR proteins in 
Drosophila melanogaster organized, descending, by RS-domain length. 
 
protein interactions. [135]. It still remains unclear the contribution of each domain during 
splicing in vivo. 
Similar to the RRM-domain, the content and the length of the SR protein RS-domains are 
conserved from Drosophila to humans, and are targeted for reversible phosphorylation at 
serine residues by multiple kinases. The phosphorylation state of the RS-domain can 
affect SR protein localization, RNA-binding, and protein-protein interactions [65, 93, 
136]. Using in vitro splicing assays, SR proteins lacking RS-domains were not able to 
complement S100 splicing extracts, but recently, it was demonstrated that the RS-domain 
of ASF/SF2 is not required for the splicing of several, but not all, pre-mRNAs. This 
reliance on the RS-domain for splicing regulation was found to be related to the strength 
of the 3’ splice site [137]. SR proteins differ in their abilities to complement splicing 
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deficient S100 extracts. Additionally, different RS-domains have been shown to differ in 
their potency when tethered to the same ESE. Furthermore, by increasing the number of 
binding sites, or length of the RS-domain, additively increased the efficiency of splicing 
[60]. This raised the possibility that differences in splicing activity between SR proteins 
could be attributed to the strengths of the RS-domains in addition to the specificity of 
RNA binding.  
Despite careful dissection of SR protein domain contribution to splicing, in vitro, there 
has never been a study that examines the contribution of each domain to regulation of 
endogenous targets. Additionally, previous studies have focused on the role for SR 
protein domains in constitutive splicing, and have never examined their requirement in 
AS.  In this chapter, we set out to identify the SR protein domains required, in vivo, for 
regulation of AS targets. We first demonstrate that an RS-domain is required for proper 
regulation of endogenous AS targets. Next, we show that the specificity and direction of 
AS regulation is dictated by the RRM-domain. Although, another SR protein’s RS-
domain can functionally substitute, the specificity and direction of splicing change relies 
on the RRM-domain.  
3.2 Materials and Methods 
3.2.1 Construction of 2x Flag-HA XL6 WT and Mutant constructs 
Full length XL6, XL6∆RS, and XL6-B52RS were PCR amplified and cloned into 
pDONR221 by BP reaction (Gateway cloning; Invitrogen). XL6-B52RS was amplified 
using a two-step PCR. First, the RRM-domain of XL6 and RS-domain of B52 were 
	   82	  
amplified, separately. Next, the purified PCR products were mixed together and 
amplified with outside primers to generate the fusion. 
XL6_FL_SP 
5- GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGTCGCGCCATCCGAGC-3 
XL6_FL_ASP 
5- GGGGACCACTTTGTACAAGAAAGCTGGGTAGTCCCTTGAAACGGA-3 
XL6∆RS_ASP 
5-
GGGGACCACTTTGTACAAGAAAGCTGGGTAACACGGGCTCGGCGCCCGCAA
A-3 
XL6-B52RS_SP 
5- GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGTCGCGCCATCCGAGC-3 
XL6_RRM_ASP 
5- CTCCGCGACGATCCTCGACTTCGCGACAGTGGCGAGCGAA-3 
B52_RS_SP 
5- TTCGCTCGCCACTGTCGCGAAGTCGAGGATCGTCGCGGAG-3 
XL6-B52RS_ASP 
5- GGGGACCACTTTGTACAAGAAAGCTGGGTAATCGTCCATGCTCTCGTT-3 
 
Next, the BP reaction was transformed into DH5a cells, plated on kanamycin plates and 
screened for positive clones. The constructs were inserted into a destination vector that 
contained the metallothionein promoter and a C-terminal 2x Flag and 2x HA tag (pMT-
C2FL2HA) by LR reaction (Gateway cloning; Invitrogen). The LR reaction was 
transformed into DH5aThe LR reaction was transformed into DH5.HA 
F vector that contained the 
3.2.2 Generation stably transfected cell lines 
400ng of pMT-C2FL2HA plasmid DNA containing XL6, XL6∆RS, and XL6-B52RS and 
40ng of plasmid carrying the gene for blasticidin resistance (pCO-BLAST) were 
transfected into 2.0 x 106 Drosophila S2 cells, seeded in a 6-well tissue culture dish, 
using Effectene transfection reagent (Qiagen) according to the manufactures protocol. 
After 48hrs, blasticidin (Invivogen) was added to the transfected cells at 25µg/ml. 
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Resistant cells were expanded, and maintained, in Schneiders media with 10%FBS and 
25µg/ml Blasticidin. 
3.2.3 Generation of dsRNA against XL6 5’ and 3’ UTRs 
dsRNA was made against the 5’ and 3’ UTRs of XL6 to using the procedure described in 
section 2.2.2. Primers used to generate the T7-DNA template were: 
T7_XL6_5UTR_S 
5-TAATACGACTCACTATAGGGAGGACCAGACACTCCCGCCTTTTGC-3 
T7_XL6_5UTR_AS 
5-TAATACGACTCACTATAGGGAGGATGTTTATTTCGCTTTTCCCCG-3 
T7_XL6_3UTR_S 
5-TAATACGACTCACTATAGGGAGGATAGAAATGTATCGGCAGCCGC-3 
T7_XL6_3UTR_AS 
5-TAATACGACTCACTATAGGGAGGATAATTTTGGCATTTAATTTAT-3 
 
3.2.4 Expression of WT and Mutant XL6 constructs in Drosophila S2 cells 
1.0 x 106 cells of each stably transfected cell line was seeded in 4 wells each of a 12-well 
tissue culture dish. 10µg of Control dsRNA or dsRNA against the UTRs of XL6 was 
added. After 48hrs, another boost of 10µg of dsRNA was added to the cells, and the 
expression of the tagged constructs was induced by adding CuSO4 at a concentration of 
100µM.  The cells were then incubated for an additional 48hrs. The cells were harvested, 
and the RNA purified using the RNeasy kit following the manufacturer’s protocol 
(Qiagen #74106).  
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3.2.5 Western-blot to determine construct expression and endogenous XL6 knock-
down 
After RNAi and expression of XL6 protein constructs, 10% of the cells were saved and 
3% loaded on a 10% SDS-PAGE gel, transferred, and blotted with antibody raised 
against XL6 according to section 2.2.5. Antibody against H3 was used as a loading 
control. 
3.2.6 RT-PCR of SR protein targets 
5µg of purified RNA added to a randomly primed/oligo d(T)15 reverse transcription 
reaction using the procedure described in section 2.2.8. PCR was performed as described 
in section 2.2.8 on AS events in Dre4, Vps35, DppIII, CG12065, and Syb. PCR was also 
performed on cDNA from an RNAi of B52, in wild-type S2 cells, to assay B52 
contribution to regulation.  
3.3 Results 
It has been proposed that SR proteins can cooperate with spliceosomal components (such 
as U1 snRNP and U2AF) in recognition of the 5’ or 3’ splice sites, and this effect is most 
likely mediated by specific interactions between the RS-domains. Interestingly, in vitro 
splicing of several pre-mRNAs do not require an RS-domain at all, and this directly 
correlates with the strength of the 3’ splice site [137]. Therefore, we set out to identify the 
SR protein domains required, in vivo, for regulation of endogenous AS targets. 
First, we engineered stably transfected S2 cells that can be induced, using a 
metallothionein promoter, to express a wild-type Flag-HA tagged XL6 (XL6-FL) and  
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Figure 3.2: Diagram of WT XL6 and variant proteins. Diagram of wild-type XL6, 
XL6∆RS, and XL6-B52RS 2xFlag2xHA tagged proteins, showing relevant domains. The 
RNA binding domain (RRM; blue), zinc-knuckle (Zn;green) and the C-terminal 
arginine/serine domain (RS) organization of copper inducible constructs.  
 
XL6 lacking the RS-domain (XL6∆RS), to examine the RS-domain requirement for AS 
regulation (Figure 3.2). RS-domains from different SR proteins differ in sequence 
composition and length, but have been demonstrated to be, functionally, substituted for 
one another in vitro (Figure 3.1). However, there are differences in potency of RS-
domains when tethered to a similar ESE. We therefore designed a mutant that substitutes 
the RS-domain of B52 for the RS-domain of XL6 (XL6-B52RS) to test whether a 
different RS-domain can functionally substitute for antagonistic and specific XL6 AS 
targets.  
Wild-type and mutant forms of XL6 were expressed in S2 cells, RNA was extracted, and 
subjected to RT-PCR. To eliminate effects from endogenous XL6, we reduced its 
expression by using dsRNA that targets the 5’ and 3’UTR of the protein. This allows  
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Figure 3.3: Expression of recombinant XL6 constructs in Drosophila S2 cells. 
Expression of endogenous and recombinant XL6 constructs in Drosophila S2 cells 
analyzed by western-blot. Expression of recombinant XL6 is assayed in the presence or 
absence of dsRNA against endogenous XL6. Histone H3 was used as a loading control. 
 
reduction of endogenous XL6 without affecting the expression of the tagged XL6 
constructs (Figure 3.3). First, we examined two AS events that are regulated by XL6 and 
B52 antagonistically (Dre4 and Vps35). XL6 is an activator of the Dre4 cassette exon and 
repressor of the Vps35 competing donor event, while B52 represses Dre4 and activates 
Vps35 AS events (Figure 3.4A;compare lanes 1 and 2 and Figure 3.4B). Over-expression 
of wild-type XL6 enhances the activation and repression of Dre4 and Vps35 AS events, 
respectively. This enhancement remains even when endogenous XL6 protein levels are 
reduced (Figure 3.4A;compare lanes 3 and 4 to 1 and 2). This demonstrates that there is 
specific, concentration dependent, regulation of these events by XL6. It also shows that 
by over-expressing XL6 the repression by B52 can be overcome.  
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Figure 3.4: Specificity of SR protein AS regulation depends on RRM-domain, and 
requires the RS-domain. (A) Semi-quantitative RT-PCR of XL6 regulated targets 
(Dre4, VPS35, DppIII) and B52 regulated controls (CG12065 and Syb) in S2 cells that 
are expressing wild-type XL6 or XL6 mutants. (B) Semi-quantitative RT-PCR of AS 
targets in the presence or absence of B52 RNAi in wild-type S2 cells. 
 
However, over-expression of XL6∆RS fail to enhance the activation of the Dre4 AS 
event, and AS isoform regulation is still sensitive to endogenous XL6 protein levels 
(Figure 3.4A;compare lanes 7 and 8 to lanes 5 and 6). Similarly, over-expression of 
XL6∆RS does not enhance the repression of the AS event in Vps35, and this event is also 
sensitive to endogenous XL6 protein levels. This demonstrates that, for Dre4 and Vps35 
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AS events, over-expression of wild-type XL6 can functionally enhance AS, but this 
regulation requires and RS-domain. 
When B52 protein level is reduced there is antagonistic regulation of Dre4 and Vps35 AS 
events. In addition to direction, it appears that when B52 is reduced there is a greater 
magnitude of splicing change. B52 regulates the largest number of AS events, and events 
regulated by B52 have an increased magnitude of splicing change as compared to XL6 
depletion (Chapter two). The RS-domain of B52 is 41 amino acids larger than the RS-
domain of XL6 (Figure 3.1). Previous studies have demonstrated that the splicing activity 
of bound SR proteins is directly proportional to the number of RS tetrapeptide sequences 
within the RS-domain, and this is related to the length of the RS-domain.  In addition to a 
greater overall length of the RS-domain, B52 has 11 RS tetrapeptide repeats, while XL6 
only has four. To test if the RS-domain from B52 can functionally substitute for the XL6 
RS-domain we over-expressed a construct that has the B52 RS-domain substituted for the 
XL6 RS-domain. Over-expression of XL6-B52RS also enhances the activation and 
repression of Dre4 and Vps35 AS events, respectively. Similar to the over-expression of 
wild-type XL6, this enhancement persists regardless of endogenous XL6 protein levels 
(Figure 3.4A;compare lanes 11 and 12 to lanes 9 and 10). Interestingly, the direction of 
splicing change when XL6-B52RS is overexpressed mimics that of wild-type XL6, even 
though endogenous B52 affects Dre4 and Vps35 antagonistically of XL6. In addition, the 
magnitude of splicing change is less with the longer B52 RS-domain. This indicates that 
the SR protein RRM-domain, and not a specific RS-domain, dictates the direction of the 
splicing change. Furthermore, the magnitude of splicing change also depends on the 
binding location of the SR protein, and less with the length of the RS-domain.  
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The cassette exon in DppIII is activated in the presence of XL6, and a modulation of B52 
protein level has no effect (Figure 3.4A;compare lanes 1 and 2). Over-expression of XL6-
FL and XL6-B52RS, but not XL6∆RS, enhance the inclusion of the DppIII AS exon. 
Similar to the AS events in Dre4 and Vps35, XL6-B52RS can enhance AS in the same 
direction as XL6-FL. However, AS events uniquely regulated by B52, and not XL6 
(CG12065 and Syb), there is little or no change in AS when XL6-FL, XL6∆RS, or XL6-
B52RS is over-expressed (Figure 3.4A and B). This indicates that the specificity of 
targets is also determined by the RRM-domain, and not the RS-domain.  
These results strongly suggest that the RS-domain of SR proteins is required for AS 
regulation, in vivo. Furthermore, RS-domains from different SR proteins can be 
functionally substituted, but do not dictate the direction of splicing change or the 
specificity of the targets. In addition, it seems that substituting a longer RS-domain with 
more RS tetrapeptide repeats from another SR protein does not correlate with the 
magnitude of splicing change. However, the location, or affinity, of binding to the target 
has the most influence on SR protein activity, and the SR protein RRM-domain defines 
these attributes.  
3.4 Discussion  
In this chapter, we analyzed the contribution of SR protein RS-domains to regulation of 
endogenous AS targets, in vivo. It is believed that the RRM-domain mediates binding to 
ESE motifs, while the RS-domain mediates protein-protein interactions with other 
splicing factors to regulate splice site selection. We demonstrate that the RS-domain of 
XL6 is required to control the regulation of the AS of the endogenous targets tested. 
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Previous, in vitro, studies in mammals suggested that the RS-domain of SF2/ASF is 
required for constitutive splicing, but is dispensable for concentration-dependent 
regulation of some AS [40]. Furthermore, it was shown that SF2/ASF RS-domain could 
be dispensed for regulation of some constitutive splicing targets [137].  While our study 
did not examine constitutively spliced targets, we examined targets that were sensitive to 
XL6 depletion, whereas the previous studies only examined targets whose splicing 
changes when dramatically high amounts of recombinant SR protein is added to the 
splicing reaction. This difference may allow our study to identify AS targets that are 
more dependent on the action of XL6, and therefore, more sensitive to XL6 RS-domain. 
Secondly, our study examined splicing changes of endogenous targets, in vivo, and the 
other studies examined splicing substrates in vitro. There are most likely are differences 
in the assembly of splicing complexes, and contribution of co-transcriptional splicing 
regulation, between the two different systems. Another in vivo study in DT40 B-cells 
demonstrated the SF2/ASF that had an RS-domain was essential for cell viability [138]. 
Reversible phosphorylation of the RS-domain has been demonstrated to affect SR protein 
RNA-binding specificity, and subsequent function in the splicing reaction. However, it 
has been shown that SR proteins lacking the RS-domain can still bind to the same 
sequence recognized by the phosphorylated full-length SR protein [93]. Therefore, it may 
be expected that over-expressing XL6∆RS may bind functional XL6 binding sites and 
have a dominant-negative effect. In our study we do not see any change in splicing 
patterns when XL6∆RS is over expressed. This could mean that XL6∆RS is not binding 
to the same binding site as XL6, or may not be able to bind RNA at all. Previous studies 
have demonstrated that phosphorylation of SR protein RS-domains are required for 
	   91	  
splice-site recognition, and dephosphorylation is required for proper splicing catalysis 
[139]. It would be interesting to assay if XL6∆RS can still bind RNA, and if so, can it 
still bind in the same location, and with the same affinity, as wild-type XL6.  
RS-domains from different SR proteins are shown to be functionally substituted for one 
another. Additionally, replacement of the RS-domain with RS dipeptides can substitute 
for the entire RS-domain [137]. RS-domains from different SR proteins, when fused to 
the bacteriophage MS2 coat protein RNA-binding domain targeted to the same region on 
a pre-mRNA, have differential strengths of splicing enhancement. The differences in 
strength were attributed to RS-domain length, and number of RS tetrapeptides [60]. In 
our study the RS-domain from B52, when substituted for the XL6 RS-domain, can 
functionally substitute in AS regulation of XL6 targets. This extends the observation that 
RS-domains can be functionally substituted for one another for regulation of AS targets, 
in vivo.  The RS-domain of B52 is larger, and contains more RS tetrapeptide repeats. 
However, we do not observe an increase in magnitude of splicing change, it is actually 
lower, when the XL6-B52RS is over-expressed. Alternatively, the apparent reduced 
activity of XL6-B52RS could result from differences in protein folding, or conformation, 
in the SR protein fusion.   
When examining targets that are regulated antagonistically by XL6 and B52, we show 
that the direction of splicing change is dependent on the XL6 RRM-domain. When the 
RS-domain from B52 is substituted for XL6 (XL6-B52RS), the direction of splicing 
change is in the direction of endogenous XL6, not B52, confirming that the RRM-domain 
of XL6 is responsible for the specificity of AS regulated targets.  Conversely, XL6-
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B52RS over-expression has little or no affect on AS targets regulated by B52 and not 
XL6.  
The observations in this chapter demonstrate that SR proteins require an RS-domain to 
regulate AS, but RS-domains from other SR proteins can be functionally substituted, in 
vivo. Additionally, RNA-binding specificity is determined by the RRM-domain, and the 
binding location on the target transcript determines the pattern of AS regulation. 
Therefore, it will be important to identify the binding location on target transcripts to 
fully understand the precise mechanism of SR protein AS regulation.  
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Chapter IV: Generation of Genome-wide RNA Binding Distribution For The SR 
Protein Family 
4.1 Introduction 
Throughout RNA metabolism, transcripts are associated with many RNA-binding 
proteins (RBPs) that coordinate multiple RNA processing and regulatory steps, which 
contribute to the ultimate expression and function of individual RNAs [140]. SR proteins 
play a significant role in multiple stages of an RNA lifecycle, and can regulate gene 
expression output at these different steps. The precise spatial arrangement of SR proteins 
on a target transcript are important for identifying direct targets, as well as uncovering 
how SR proteins regulate different RNA processes, including alternative pre-mRNA 
splicing.  
Regulation of splicing is highly complex, and is the result of the combinatorial regulation 
of multiple splicing factors binding to several regulatory sequences in the RNA.  For 
example, the SR proteins XL6 and Rbp1, in collaboration with Tra and Tra2, have been 
shown to bind to specific regulatory elements in the Drosophila transcript doublesex to 
regulate splicing [61]. Additionally, there are position-dependent effects on AS 
regulation. A mammalian SF2/ASF or SRp40 binding site was inserted at different 
locations on an alternative exon, and depending on the position, exerted different effects 
on the AS pattern [59]. These studies indicate that splicing can be regulated by multiple 
SR proteins, along with other RBPs, in a combinatorial fashion, and that the binding 
location of the SR protein in the target pre-mRNA determines whether it functions as an 
enhancer or silencer of splicing.  
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There have been several approaches taken to identify the physiological targets, and map 
protein-RNA interactions, to determine SR protein effects on the transcriptome. 
Biochemical methods such as SELEX, electrophoretic mobility shift assay (EMSA), and 
RNA protection assays were first used to identify high-affinity binding sites for several 
SR proteins. These binding sites were purine-rich, and resembled ESE sequences [94]. 
Functional SELEX was developed to select for sequences that are bound, but will also 
promote splicing, using S100 extract. This strategy identified more redundant binding 
motifs between the SR proteins than the traditional SELEX method, indicating that 
binding specificity, in vivo, may depend on additional factors other than simple sequence 
recognition [58]. The motifs identified from traditional and functional SELEX have been 
used to scan for potential, endogenous, ESEs that are regulated by SR proteins. 
One problem with these biochemical approaches is that they do not assay SR protein 
RNA-binding in a native cellular context, to endogenous targets. To preserve the cellular 
context, RNA immunoprecipitation (RIP) was combined with RT-PCR, or microarray 
analysis (RIP-CHIP), to identify nascent RNA-protein interactions. RIP-CHIP was used 
to identify the genome-wide binding locations of four members of the Drosophila hnRNP 
family of splicing regulators [74].  However, these methods are of low resolution, and 
can identify indirect RNA-binding interactions.  
Most RBPs recognize short RNA motifs, and bind to several positions on a target RNA. 
Therefore, it is important to determine the landscape of RNA-binding of and RBP on a 
target RNA.  To determine precise RBP binding sites, and reduce nonspecific binding, 
CLIP (UV cross-linking and immunoprecipitation) was developed to identify RNA 
targets of RBPs. CLIP involves the UV irradiation of living cells or tissue to induce the 
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formation of covalent cross-links only at sites of direct contact between proteins and 
RNA. Once the cells are lysed, protein-RNA complexes are immunopurified, followed by 
partial RNase digestion to generate short RNAs specifically bound to the RBP. These 
RNAs are subjected to reverse-transcription to generate bound cDNAs. In combination 
with high-throughput sequencing (CLIP-Seq), precise RBP binding locations, genome-
wide, can be determined. CLIP-Seq was first used to uncover the binding landscape of 
the neural specific RBP, NOVA, in the mammalian brain [100]. It has also been used for 
other RBPs, including mammalian SF2/ASF and hnRNP family members [101, 112].  
Although the resolution of CLIP-Seq is greater than RIP-CHIP, the resolution of binding 
site detection corresponds with the length of the digested RNA. In addition, it was 
demonstrated that the reverse-transcription reaction stops at many nucleotides that are 
cross-linked to the peptides that remain after proteinase K digestion, and are lost during 
the standard CLIP library preparation [105]. A modification of the CLIP protocol, termed 
iCLIP (individual nucleotide resolution CLIP), allows the truncated cDNAs to be 
sequenced.  This identifies the location of the cross-link position, and the ability to obtain 
individual nucleotide resolution of cross-link sites.  iCLIP replaces one of the RNA 
ligation steps in CLIP with a, more efficient, intramolecular cDNA circularization to 
capture the truncated cDNAs. iCLIP was first used to identify the binding footprint of 
hnRNP C to specific uridine rich tracts in order to regulate AS [104].  Subsequently, 
iCLIP has been used to identify the binding locations of two mammalian SR proteins 
(SRSF3 and SRSF4). This study found that these two SR proteins bind to unique 
locations on diverse types of RNAs, and can cross-regulate the expression of other SR 
proteins [107].  Although this study provides insights into SR protein function, it did not 
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examine SR protein binding positions, and their role in regulating AS. Additionally, the 
previous study only profiled the binding locations of two members of the SR protein 
family.  
In this chapter, we determine the in vivo binding location, transcritpome-wide, for all 
eight members of the Drosophila SR protein family using iCLIP-Seq. Our analysis shows 
that SR proteins bind to an overlapping set of genes, but mostly bind to distinct locations 
on the target RNAs. We further demonstrate that SR proteins can bind to a functionally 
diverse set of RNAs, including intronless and non-coding RNAs (ncRNAs), and identify 
high-affinity binding sites of these targets. The combination of iCLIP-Seq and RNA-Seq 
reveal position-dependent regulation of AS, and interrelated RNA splicing maps for 
many SR proteins. These results characterize SR protein binding in respect to its role in 
AS regulation, but also implicate SR proteins in the regulation of other aspects of RNA 
processing, further supporting SR protein’s widespread contribution to gene expression 
regulation.  
4.2 Materials and Methods 
4.2.1 Construction of 2x Flag-HA SR protein constructs 
Full length SC35, SF2, SRp54, XL6, Rbp1, B52, Rsf1, and Rbp1-Like were PCR 
amplified and cloned into pDONR221 by BP reaction (Gateway cloning; Invitrogen). 
Primers used for PCR for cloning into pDONR221:  
SC35_FL_SP 
5-GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGAGCAACGGTGGTGGT-3 
SC35_FL_ASP 
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5-GGGGACCACTTTGTACAAGAAAGCTGGGTAGGAGCGACTGCGACT-3 
SF2_FL_SP 
5-GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGGGATCACGCAACGAG-3 
SF2_FL_ASP 
5-GGGGACCACTTTGTACAAGAAAGCTGGGTAATAGTTAGAACGTGA-3 
SRp54_FL_SP 
5-GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGGCTGGCGGCAACACC-3 
SRp54_FL_ASP 
5-GGGGACCACTTTGTACAAGAAAGCTGGGTAGGGCGAGTTGGAGAT-3 
XL6_FL_SP 
5- GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGTCGCGCCATCCGAGC-3 
XL6_FL_ASP 
5- GGGGACCACTTTGTACAAGAAAGCTGGGTAGTCCCTTGAAACGGA-3 
Rbp1_FL_SP 
5-GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGCCGCGATATAGGGAG-3 
Rbp1_FL_ASP 
5-GGGGACCACTTTGTACAAGAAAGCTGGGTAGAGTTGCAAGTTGAA-3 
B52_FL_SP 
5-GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGGTGGGATCTCGAGTG-3 
B52_FL_ASP 
5-GGGGACCACTTTGTACAAGAAAGCTGGGTAATCGTCCATGCTCTC-3 
Rsf1_FL_SP 
5-GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGTCCAGCATGGGTGAT-3 
Rsf1_FL_ASP 
5-GGGGACCACTTTGTACAAGAAAGCTGGGTAGAATCGATGGTTTCC-3 
Rbp1-Like_FL_SP 
5- GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGCCACGCTACCGTGAA-3 
Rbp1-Like_FL_ASP 
5- 
GGGGACCACTTTGTACAAGAAAGCTGGGTAATGGCGGTCCCTGGAGTCGGA-3 
 
 
Next, the BP reaction was transformed into 
DH5aext, the BP reaction was transformed into DH5GAGTCGGA-3Rbp1-Like were PC
R amplified and cloned into pDONR221 by BP reactionet of RNAs, includinmetallothion
ein promoter and a C-terminal 2x Flag and 2x HA tag (pMT-C2FL2HA) by LR reaction 
(Gateway cloning; Invitrogen). The LR reaction was transformed into 
DH5aetallothionein promoter and a C-terminal 2x Flag and 2x HA tag (pMT-C2F 
4.2.2 Generation stably transfected cell lines 
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400ng of pMT-C2FL2HA plasmid DNA containing either SC35, SF2, SRp54, XL6, 
Rbp1, B52, Rsf1, or Rbp1-Like, and 40ng of plasmid carrying the gene for blasticidin 
resistance (pCO-BLAST) were transfected into 2.0 x 106 Drosophila S2 cells, seeded in a 
6-well tissue culture dish, using Effectene transfection reagent (Qiagen) according to the 
manufactures protocol. After 48hrs, blasticidin (Invivogen) was added to the transfected 
cells at 25µg/ml. Resistant cells were expanded, and maintained, in Schneiders media 
with 10%FBS and 25µg/ml Blasticidin. 
4.2.3 iCLIP protocol 
Performed iCLIP as previously described (Figure 4.1) [104]. 6.0 x 106 SR protein stably 
transfected S2 cells were seeded in a 10 cm dish, and protein expression induced by 
adding 100 µM CuSO4 for 48hrs.  Media was removed and cells were covered with ice-
cold PBS, and subjected to UV irradiation (150mJ/cm2 at 254nm). Cells were harvested 
into microtubes, and pelleted by centrifugation for 5 min at 1,000g. Cells were washed 
once with PBS, pelleted, and resuspended in 1ml lysis buffer (50mM Tris-HCl, pH 7.4; 
100mM NaCl; 1% NP-40; 0.1% SDS; Protease inhibitory cocktail tablet (Roche)). 
Prepare a 1/500 dilution of RNase I (Ambion, AM2295) Add 10µl of RNase I dilution 
and 2µl Turbo DNase, to the cell lysate. For control samples (-UV and +UV) make a 1/50 
dilution of RNase I for a high RNase sample. Incubate the samples for exactly 3 min. at 
37˚C shaking at 1,100 rpm. Transfer to ice. Centrifuge at 13,000g for 20min at 4˚C to 
clear the lysate.  
For magnetic bead preparation, add 50µl of anti-FLAG M2 magnetic beads (Sigma, 
M882) per experiment to a fresh microtube. Wash beads 2x with lysis buffer. Add the  
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Figure 4.1: Schematic overview of iCLIP procedure. RNA adapter (light gray bar); 
adapter sequence (blue bar); random molecular barcode (red bar); cross-linked 
polypeptide (orange triangle); cDNA region (Dark gray bar).  
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digested cell lysate to beads. Rotate the samples for 2hr at 4˚C. Discard the supernatant 
and wash the beads 2x with 900µl high-salt buffer (50mM Tris-HCl, pH 7.4; 1M NaCl; 
1mM EDTA; 1% NP-40; 0.1% SDS) and 2x with 900µl wash buffer (20mM Tris-HCl, 
pH 7.4; 10mM MgCl2; 0.2% Tween-20).   
For dephosphorylation of 3’ ends, beads were resuspended in 20µl PNK mix (17µl water; 
2.0µl PNK buffer [NEB]; 0.5µl PNK enzyme [NEB]; 0.5µl RNAsin [Promega]) and 
incubate for 20 min. at 37˚C. Add 500µl wash buffer and then wash with 1x high-salt 
wash buffer, followed by 2x with wash buffer.   
For linker ligation to RNA 3’ ends, beads were resuspended in 20µl ligation mix (2.0µl 
ligation buffer [NEB]; 2µl ATP [NEB]; 1.5µl 3’ Linker [20µM]; 1.0µl RNA ligase 
[NEB]; 0.5µl RNasin [Promega]; 4.0µl PEG400 [Sigma]; 9.0µl water). Incubate at 16˚C 
overnight. Add 500µl wash buffer and then was with 2x high-salt buffer and 2x wash 
buffer. 
For labeling the 5’ end, beads were resuspended in 10µl of hot PNK mix (7.5µl water; 
1.0µl PNK buffer [NEB]; 1.0µl 32P-g-n 10µl of hot PNK mix (7.5µl and incubate for 5 
min. at 37˚C. Hot PNK mix was removed and 22µl of 1x Nupage loading buffer (LDS; 
Invitrogen) was added to the beads. Beads were incubated for 10 min at 70˚C. 2µl of the 
sample was saved for a western blot.  
Samples were loaded on a 10% NuPAGE Bis-Tris gel (Invitrogen) according to the 
manufacturer’s instructions. The gel was transferred to a nitrocellulose membrane using 
the iBLOT (Invitrogen) according to manufacturer’s protocol. The membrane was rinsed 
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with PBS, wrapped in Saran wrap, and exposed to Kodak film MS from 30 min. to 
overnight.  
The membrane was cut using the autoradiograph to isolate the protein-RNA complexes, 
and placed in a new microtube.  200µl of PK buffer (100mM Tris-HCl, pH 7.4; 50mM 
NaCl; 10mM EDTA) and 10µl proteinase K (Roche, 03115828001) was added to the 
membrane and incubated for 20 min at 37˚C shaking at 1,100 rpm. Next 200µl PK buffer 
plus 7M Urea was added and incubated for an additional 20 min. at 37˚C. The solution 
was collected and added to 400µl RNA phenol/chloroform (Ambion, 9722), and 
incubated for 5 min. at 30˚C shaking. The sample was centrifuged for 5 min. at 13,000 
rpm to separate the phases. The aqueous phase was transferred to a new tube containing 
0.5µl glycoblue (Ambion, 9510), 40µl 3M sodium acetate pH 5.5, and 1ml 100% ethanol. 
RNA was precipitated overnight at -20˚C. RNA was centrifuged for 20 min. at 15,000 
rpm at 4˚C, and the pellet washed with 500µl 80% ethanol and dried. 
For the reverse-transcription reaction the pellet was resuspended in 10µl water, 1µl Rclip 
primer, and 1µl dNTPs (10mM). Reaction was incubated at 70˚C for 5 min. then cooled 
to 25˚C. Next, 8µl of RT mix (4µ FS buffer; 2µl 0.1M DTT: 1µl Superscript III 
[Invitrogen]; 1µl RNasin) was added and incubated 10 min at 42˚C, 45 min. at 50˚C, 15 
min at 55˚C, and 5 min at 90˚C before cooling to 4˚C. Volume was brought to 100µl with 
TE buffer and precipitated overnight as describe previously.  
For size separation, cDNA pellet was resuspended in 6µl water and 6µl 2x TBE-urea 
loading buffer (Invitrogen), and heated at 80˚C for 5 min before loading on a precast 6% 
TBE-urea gel (Invitrogen). The gel was run for 40 min at 180V as described by the 
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manufacturer. Three bands were cut at 120-200nt (high), 85-120nt (medium), and 70-
85nt (low) and crushed in 400µl TE in a microtube. cDNA was allowed to diffuse for 2hr 
at 37˚C.  The supernatant was purified in a Costar SpinX column (Corning) containing 
two 1cm glass pre-filters (Whatman, 1823010) spun for 1 min at 13,000rpm. cDNA was 
precipitated overnight as described previously.  
In order to circularize the cDNAs, the pellets were resuspended in 8µl ligation mix (6.5µl 
water; 0.8µl 10x CircLigase Buffer II; 0.4µl 50mM MnCl2; 0.4µl Circligase II 
[Epicentre]) and incubated for 1hr at 60˚C. Next 30µl of oligo annealing mix is added 
(26µl water; 3µl FastDigest Buffer [Fermentas]; 1µl Cut Oligo [10µM]) and incubated 1 
min at 95˚C, then the temperature was decreased 1˚ every 20 seconds until 25˚C is 
reached. Then 2µl BamHI [Fast Fermentas] was added and incubated 30 min. at 37˚C. 
cDNA was precipitated as described previously. 
To PCR amplify the library, the pellets are resuspended in 19µl of water and added to a 
PCR mix (1µl primer mix P5/P3 solexa [10µM each]; 20µl Accuprime Supermix 
[Invitrogen]). PCR was run using the following program: 95˚C for 5 min, then 30-35 
cycles of 95˚C for 15 seconds, 65˚C for 30 seconds, and 68˚C for 30 seconds, then a final 
extension at 68˚C for 3’. 1µl of PCR products were analyzed and quantified using a DNA 
1000 chip on an Agilent bioanalyzer.  
Primers: 
L3  /5rApp/AGATCGGAAGAGCGGTTCAG/3ddC/ 
Cut_Oligo GTTCAGGATCCACGACGCTCTTCaaaa 
P5/P3 Illumina Paired-end Primer mix 
  X33 = 5’ Phosphate 
Rclip1 X33AACCNNNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rclip2 X33ACAANNNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rclip3 X33ATTGNNNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
	   103	  
Rclip4 X33AGGTNNNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rclip5 X33CGCCNNNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rclip6 X33CCGGNNNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rclip7 X33CTAANNNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rclip8 X33CATTNNNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rclip9 X33GCCANNNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rclip10  X33GACCNNNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rclip11  X33GGTTNNNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rclip12  X33GTGGNNNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rclip13  X33TCCGNNNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rclip14  X33TGCCNNNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rclip15  X33TATTNNNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rclip16  X33TTAANNNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
 
4.2.4 High-throughput sequencing and mapping 
High-throughput sequencing of iCLIP cDNA libraries from two replicate experiments for 
each SR protein were sequenced multiple times on an Illumina HiSeq 2000 with a 50nt 
run length. Sequence reads included a 5nt random barcode and a 4nt unique experiment 
identifier. The adapter sequences were trimmed using fastx_clipper. Next duplicate reads 
that had exact identity, including the experiment and random barcode, were removed 
using fastx_collapser. The resulting cDNAs (Refered to as CLIP Tags) were aligned to 
the Drosophila melanogaster genome (v5.22) using bowtie.  
4.2.5 Identification of iCLIP-Seq clusters 
Significant clusters were calculated by first determining the CLIP Tag number cutoffs 
using the Poisson distribution as identified in Polymenidou et al [141].  CLIP Tags were 
divided into Uxons (can be exonic) and Introns (only intronic). Nucleotides that had 
CLIP Tags above background (p-cutoff  ≤ 0.01) were identified as significant cross-
linked nucleotides. Nucleotides that are within 15nt of one another were merged into a 
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CLIP cluster. Identified CLIP clusters from each replicate experiment were merged into 
experimental CLIP clusters. CLIP clusters genomic annotations were assigned based on 
gene annotations given by Flybase (v5.22).  
4.2.6 Motif analysis 
De novo motif finding was implemented using 1000 random SR protein CLIP clusters 
and the MEME-CHIP Suite that includes DREME. DREME is a motif discovery 
algorithm specifically designed to find short motifs from large datasets [142]. DREME 
was originally designed to identify transcription factor binding sites from CHIP-Seq data, 
but can be utilized to identify RBP binding motifs as well. The background used was the 
1000 input sequences were shuffled preserving nucleotide composition. Consensus motifs 
that E-value ≤ 0.01 were used. The E-value is the enrichment p-value times the number 
of motifs tested. P-values are calculated using the Fisher-exact Test for enrichment of the 
motif in the positive sequences.  
MotifBS (http://compbio.berkeley.edu/people/ed/motifBS.html) was used to search the 
SR protein regulated AS genes with the identified motif, and return scores for the 
presence of the motif in the gene. The unaffected AS genes were also searched in order to 
obtain background scores. The cumulative distribution of scores for the regulated and 
background genes were plotted. 
4.2.7 RNA splicing maps 
iCLIP CLIP Tags were mapped to the affected cassette exon AS events detected by 
RNA-Seq (described in chapter two) at each nucleotide position in four regions (300nt 
	   105	  
centered at each splice site). The relative density was calculated at each nucleotide in the 
regions, by dividing the number of CLIP Tags at a given nucleotide position by the total 
number of CLIP Tags in all regions. For each SR protein, cassette exons were separated 
into three groups, repressed, activated, and unchanged. Using R, we plotted at each 
nucleotide position the relative density of iCLIP CLIP Tags of activated, repressed, and 
unchanged cassette exons. The same was performed on competing acceptor (5’ss) 
splicing events.  
4.3 Results 
4.3.1 Mapping SR protein binding to RNAs at nucleotide resolution with iCLIP-Seq 
Previous studies have demonstrated that, in order to control AS, members of the SR 
protein family bind cis-acting elements (ESEs and ISEs) in the target pre-mRNA. 
However a detailed, global, description of bound RNAs for a majority of SR proteins has 
yet to be determined. Our previous study of AS changes when individual SR proteins are 
depleted, reveal that multiple SR protein family members co-regulate a majority of AS 
events (Chapter 2). One question raised by this observation is whether joint regulation 
requires the binding of multiple proteins, and if so, are the proteins binding to unique or 
overlapping regions on the target transcript. Therefore, it is important to identify the 
precise binding locations for all SR proteins on target transcripts to identify the 
mechanism of AS regulation by this family of conserved splicing regulators. 
Furthermore, SR proteins have been implicated in multiple steps of RNA metabolism, so 
identifying global RNA targets, and the binding location on these targets, will provide 
insights into SR protein regulation of other RNA processing events.  
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We used the iCLIP method (Described in 4.1) to identify, direct, SR protein binding 
positions on RNAs, in vivo.  All eight SR proteins were immunopurified via the FLAG 
tag encoded on stable transgenes transfected in Drosophila S2 cells. Expression of the SR 
protein transgene is under the control of an inducible metallothionein promoter. After 
48hrs of induction, exogenous SR proteins are detected, and are not grossly 
overexpressed when compared to endogenous SR protein levels (Figure 4.2A). Previous 
analysis showed that the FLAG-tagged SR proteins could functionally rescue the AS 
patterns of the endogenous proteins (Chapter 3), and therefore should recapitulate 
interactions with target RNAs.  
iCLIP experiments were performed, in duplicate, for all eight Drosophila SR proteins. 
Each SR protein was specifically and efficiently immunopurified from cell extracts, and 
SR protein-RNA complexes were isolated after in vivo UV-cross-linking. The purified 
SR protein-RNA complex was significantly reduced or absent when UV-cross-linking 
was omitted (Figure 4.2B). Cross-linked RNA was purified, reverse-transcribed, and PCR 
amplified in preparation for next-generation sequencing.  
The resulting libraries were sequenced using Illumina Hi-Seq 2000, and generated 
between 168 and 432 million sequence reads per SR protein sample. Between 3.7 and 
39.0 million sequences aligned uniquely to the Drosophila melanogaster genome, 
allowing for two mismatches, and were greater than 24nt in length. Next, removing 
identical reads, including the random and experimental barcode region, eliminated PCR 
amplification artifacts (Figure 4.3A). In addition, reads that had the same experimental 
and random barcode, were also collapsed in order to only count unique cDNA molecules 
(CLIP Tags). The resulting data set generated between 38,695 and 5.9 million unique  
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Figure 4.2: Analysis of cross-linked SR protein-RNA complexes using iCLIP. (A) 
Western-blot of protein extracts after induction of tagged-SR protein for 48hr with 
100µM CuSO4.  Extracts were blotted with antibodies that recognize the endogenous 
(Lower band) and exogenous (Upper band). (B) Autoradiograph of SR-RNA complexes 
digested with two concentrations of RNase, in the presence or absence of UV-cross-
linking. The red boxes are the RNA that was excised and used for iCLIP-Seq library 
preparation. Below are western-blots of the immunopurified protein (WB).  
 
CLIP Tags for each SR protein replicate (Figure 4.3B). We next used a cluster finding 
algorithm to identify significant SR protein binding sites from clusters of CLIP Tags, 
with a conservative threshold of P ≤ 0.01. This stringent cut-off has the potential of 
removing true binding sites, but will limit our analysis to the most significantly bound 
regions. This analysis generated between 5,752 and 82,096 CLIP clusters for each SR 
protein replicate (Figure 4.3B). A limitation to iCLIP, and all CLIP methods, is that the 
libraries generated are of limited complexity. This is due to the low efficiency of UV-
cross-linking, and the RNA ligation reaction. The iCLIP libraries generated for each 
replicate are most likely not saturated for all the bound RNA molecules, and only a few 
CLIP Tags represent many binding sites. However, all of the libraries were sequenced to 
saturation, indicating that the difference between replicates comes from the iCLIP 
procedure, and is not due to lack of sequencing. In order to minimize loss of true SR 
protein binding sites, we merged the identified CLIP clusters from each replicate. This 
produced between 16,004 and 102,04 CLIP clusters for each SR protein (Figure 4.3B). 
This analysis reveals that individual SR proteins bind a different number of RNA regions. 
XL6 binds the most while SF2 binds the fewest regions. This difference could be due to 
the iCLIP procedure (protein expression, cross-linking efficiency), but most likely is due 
to inherent differences in RNA binding distribution between different SR proteins. 
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Figure 4.3: iCLIP mapping information. (A) Number of RNA-Seq reads per 
experiment and alignment information. (B) Number of molecules were identified for each 
replicate using the random barcode.  The number of significant CLIP clusters was 
calculated for each replicate, and then merged for each SR protein experiment.  
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4.3.2 Global landscape of RNA transcripts bound by SR proteins 
Examination of SR protein CLIP clusters reveals that SR proteins bind to multiple 
locations across RNA sequences, and the same transcript can display cross-linking by 
multiple SR protein family members. This is exemplified when examining cross-linking 
of four SR proteins (B52, Rbp1, SRp54, and XL6) on two SR regulated transcripts. Both 
Dre4 and CG6084 display CLIP clusters for all four SR proteins (Figure 4.4A and B). 
While some clusters overlap, many CLIP clusters map to distinct regions of the 
transcripts. In addition, B52 and XL6 have many more CLIP clusters than Rbp1 and 
SRp54 on the Dre4 transcript, but all four SR proteins have a similar number of CLIP 
clusters on CG6084 (Figure 4.4A and B). These examples demonstrate that multiple SR 
proteins bind to target RNAs with different specificities. Although multiple SR proteins 
can bind overlapping regions, many regions show distinct binding for specific SR 
proteins.  
To gain a better understanding of SR protein binding events, genome-wide, we profiled 
their binding on all annotated transcripts. We detected significant CLIP clusters in 
between 5,679 (SF2) and 9,952 (SRp54) genes for each SR protein (Figure 4.5A). We 
found clusters on greater than 90% of genes that are regulated at the level of AS by 
individual SR proteins. To test whether iCLIP captured binding on only the highly 
expressed genes, we compared the bound genes to our S2 cell expression data from 
RNA-Seq. Genes identified from RNA-Seq of S2 cells (Chapter 2) were separated into 4 
quartiles of expression based on RPKM value. SR protein CLIP clusters were identified 
in genes at all four quartiles of expression, including genes not detected by RNA-Seq 
(Figure 4.5A). In general, most bound genes have one SR protein CLIP cluster, but on  
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Figure 4.4: SR proteins bind to distinct positions in Drosophila RNAs. (A) Dre4 gene 
with B52, Rbp1, SRp54, and XL6 CLIP Tags and CLIP Clusters. The numbers on the left 
represent the number of CLIP tags in the window. The alternatively spliced exon is in 
red. (B) CG6084 gene with B52, Rbp1, SRp54, and XL6 CLIP Tags and CLIP Clusters. 
The numbers on the left represent the number of CLIP tags in the window. The 
alternatively spliced exon is in red.  
 
average there are between 2.9 and 10.6 CLIP clusters per transcript depending on the 
protein, with a maximum of 60-313 CLIP clusters in Ten-m (SC35, XL6, Rbp1, B52, 
Rsf1), Pum (SF2, Rbp1L), and Klar (SRp54; Figure 4.5B and C). These three genes have 
extensive involvement in neurogenesis and contain large introns that need to be 
efficiently spliced. From this analysis, XL6 is a more promiscuous, and binds to more 
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RNAs, and to multiple locations, on the transcripts. Whereas, SF2 binds a smaller 
number of genes, and on average, fewer locations on the RNA.  
A previous study using the two mammalian SR proteins SRSF3 and SRSF4 demonstrated 
that the two SR proteins bound to distinct genes, with little overlap of bound genes 
between the two [107].  Contrary to this study, we observed the binding of multiple SR 
proteins on Dre4 and CG6084 (Figure 4.4 A and B). Indeed, greater than 94% of the 
genes bound by each SR protein are also bound by at least one other SR protein family 
member (Figure 4.6A). However, when examining the overlap of the CLIP clusters, we 
observe a decrease in clusters that overlap on the bound targets (greater than 42% in all 
cases; Figure 4.6B). This suggests that while SR proteins bind to a similar set of 
transcripts, they bind to distinct, and specific, locations. One caveat is that since we are 
not saturating our cDNA libraries, this lack of overlap could be due to under sampling of 
bound RNA molecules. However, even the samples with the lowest amounts of CLIP 
clusters are bound to unique positions, and this observation of distinct binding is 
consistent with previous studies of SR protein binding to target RNAs.   
Next, we examined the categories of transcripts, and the different functional regions 
within these transcripts, that are bound by SR proteins. Analysis of the frequency with 
which SR protein CLIP clusters were mapped to gene regions revealed that SR proteins 
bind to a high number of protein coding genes (> 98% CLIP clusters), within exonic 
sequences (> 53% CLIP clusters; Figure 4.7A). Despite the fact that introns make up a 
larger sequence space (62.5% of the genome), this enrichment of exonic binding reflects 
the known role for SR proteins as binding to ESE elements in pre-mRNA splicing, or 
other post-splicing activities. Within the exonic sequences, SR proteins mostly bind  
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Figure 4.5: SR proteins bind a large number of genes . (A) Number of genes that 
contained an SR protein CLIP cluster, grouped by gene expression level. (B) Box plot 
illustrating the distribution of the number of CLIP clusters per gene for each SR protein 
sample. Black circles are the outliers. (C) Table displaying the minimum (min), average, 
maximum (max), and most frequent (mode) number of CLIP clusters per gene for each 
SR protein experiment.  
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exons in the coding region, but have a slight enrichment for binding within the 5’ UTR 
region (Figure 4.7A).  
In addition to binding in protein coding genes, SR proteins can also bind non-coding 
RNAs (Figure 4.7A). SR protein binding to long ncRNAs for transport and stability, as 
well as, SR protein regulation of miRNA biogenesis has been previously shown [143, 
144]. SR protein CLIP clusters were found in all the major types of ncRNAs (Figure 
4.7B).  The most abundant classes of ncRNAs with CLIP clusters were snoRNAs and 
tRNAs.  snoRNAs are a class of small RNAs that guide RNA modifying enzymes, and 
tRNAs are a vital link between RNA and amino acids during protein translation. SR 
proteins have never been implicated in snoRNA or tRNA biogenesis. The extensive 
binding to these ncRNAs could indicate a novel role for SR proteins in the regulation of 
snoRNA and tRNA function, which could ultimately affect protein expression.  
4.3.3 Consensus in vivo binding motifs for the SR proteins 
Several SR protein-binding motifs have been identified using in vitro SELEX procedures.  
These binding sites are purine-rich sequences that closely resemble identified ESE 
elements, or 5’ splice sites. However, using functional SELEX, it was revealed that SR 
proteins recognize more degenerate sequences, indicating that SR protein binding is more 
complex in vivo. In order to reconcile the differences in SR protein binding sites using 
different experimental methods, efforts to identify endogenous SR protein binding sites 
have been undertaken. Two studies have used CLIP methods to uncover the in vivo 
binding motifs of SF2/ASF (SRSF1), SRp20 (SRSF3) and SRp75 (SRSF4) in 
mammalian cell culture [107, 145]. To identify the, in vivo, binding motifs for the eight  
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Figure 4.6: SR proteins bind a similar set of genes at unique positions. (A) 
Percentage of bound genes that are bound uniquely (red) or by one or more other SR 
proteins (overlapping; gray). (B) Percentage of CLIP clusters that overlap with a CLIP 
cluster of another SR protein (overlapping CLIP clusters; gray) or do not overlap with 
another SR protein cluster (unique CLIP cluster; red).  
 
Drosophila SR proteins, we used the MEME-CHIP suite, that allows for the 
identification of short binding motifs from large datasets, to identify enriched binding 
motifs from SR protein CLIP clusters (Figure 4.8). The binding motif for mammalian 
SRp20 was determined to be CU-rich excluding Gs, using, in vivo, binding data. One of 
the top five pentamers identified was UCAAC [107]. Mammalian SRSF3 has been show 
to be very similar to XL6, Rbp1, and SRp54. Additionally, Rbp1 and XL6 have been 
demonstrated to be interchangeable for binding to the splicing enhancer in Drosophila 
doublesex [61]. Similar to their mammalian homolog, XL6, Rbp1, and SRp54 bind to 
similar CU-rich motifs that lack Gs (Figure 4.8).  
Interestingly, Rbp1L, that has an RRM-domain that is 99% similar (differs by only two 
amino acids) to Rbp1, has a different binding motif than Rbp1 (Figure 4.8). Rbp1L’s 
motif (GA[UA]G[AGU]) includes Gs, but is very similar to the ESE motif (GAAGAA) 
that was identified in vitro, and found to enhance splicing in vivo [89]. This reveals that 
even a slight difference in aa composition in the RRM-domain can influence binding site 
specificity.  
Mammalian SF2/ASF was shown to bind to the purine-rich UG[GA][AU]G[AG]A motif 
in vivo [145]. Similarly, Drosophila, SF2 binds to a purine-rich G[GC]UGGA motif. 
Binding motifs for the mammalian homologs of SC35, B52 and Rsf1 have not been  
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Figure 4.7: Distribution of SR protein CLIP clusters within RNA classes and 
transcript regions. (A) The proportion of CLIP clusters that mapped to different regions 
on bound transcripts for each SR protein. The proportion of genomic space is used as a 
reference (Universe). (B) The proportion of CLIP clusters that mapped to common types 
of non-coding RNA for each SR protein. The proportion of genomic space for each 
feature is used as a reference (Universe).  
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determined in vivo. However, Drosophila SC35 and B52 bind to a similar motif that was 
determined using SELEX [95, 146]. The binding motif for Rsf1 has never been 
determined, but is very similar to XL6 binding motif, and resembles an ESE (Figure 4.8).  
Next, we examined the subset of genes that exhibit differential splicing when an 
individual SR protein is depleted (Chapter 2) for the extent of enrichment of the 
identified motif from iCLIP. We found that in all cases there was a high fraction of genes 
that had at least one occurrence of the SR protein-binding motif (Figure 4.9; blue line). 
We compared the distribution of this fraction, to the distribution of the fraction of genes 
that had a enriched motif score in the genes that are not AS regulated by the given SR 
protein, and found that as the motif score increased there was a smaller fraction of genes 
that contained the motif in the unregulated genes (Figure 4.9; red line). SC35, XL6, and 
B52 had only a slight enrichment over the background, while SRp54, SF2, Rbp1, Rsf1, 
and Rbp1L had a much larger enrichment (Figure 4.9). This indicates that there is a slight 
enrichment of identified SR protein consensus motifs in AS regulated genes as compared 
to genes not AS regulated. This observation supports the idea that there is a stricter 
requirement for a strong, or multiple, SR protein-binding motifs in AS regulated targets, 
compared to transcripts that are not regulated or constitutively spliced.  
This analysis reveals that SR proteins bind to elements that resemble ESE motifs, and to 
motifs consistent with previously determined binding motifs for their mammalian 
homologs.  In addition, Several SR proteins share a related binding motif (Rbp1 and 
SRp54), while others have a different, specific motif (SC35, SF2, XL6, B52, Rsf1, and 
Rbp1L). This suggests that SR proteins bind to specific motifs in order to regulate AS, 
and other RNA processing events.  
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Figure 4.8: SR proteins bind to specific motifs, in vivo. Graphical representation of 
consensus binding motifs derived for each SR protein. Height of each bar shows the 
information content at each position of the binding motif in bits (log-odds in base 2).  
 
4.3.4 SR protein RNA splicing maps 
In order to regulate pre-mRNA splicing, previous studies suggest that SR proteins bind to 
pre-mRNAs, primarily within exons, to recruit core spliceosomal components to nearby 
splice sites. Our previous analysis of CLIP clusters revealed a bias towards binding in 
exonic regions of annotated transcripts (Figure 4.7A). To map SR protein-binding 
positions, within exons and introns, we mapped the relative density of SR protein CLIP 
Tags 300nts around all 3’ and 5’ splice sites (Figure 4.10). As expected, mapping of SR 
protein CLIP Tags showed a very strong preference for exonic regions for all SR 
proteins. In addition, the density of CLIP Tags was more pronounced in exonic regions 
within 75nts of the acceptor or donor splice sites. SRp54 had prominent peaks within the 
intronic regions 10-20nt upstream of the 3’ss suggesting that SRp54 interaction with 
intronic sequences could regulate splicing. In conclusion, SR proteins preferentially 
contact exonic sequences, with an increase in density close to the splice sites. This is 
consistent with the model that SR proteins regulate pre-mRNA splicing by functioning as 
exonic splicing enhancers.  
To determine the pattern of position-dependent binding of the SR proteins in relation to 
their role in regulating AS, we mapped the relative density of CLIP Tags on SR protein 
activated or SR protein repressed AS events identified for each SR protein (Chapter 2).   
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Figure 4.9: Distribution of SR protein motifs in regulated AS targets. Cumulative 
distribution of the presence of at least one occurrence of the SR protein consensus motif 
in the genes identified as being regulated by individual SR proteins at the level of AS 
from RNA-Seq (Chapter 2; blue bar) and not regulated (red bar).  
 
To calculate the density we divide the number of CLIP Tags at any given nucleotide 
(400nt around each splice site) by the total number of CLIP Tags across the alternative 
region. The average relative density is then calculated for all AS events at every position. 
A similar density was also calculated on ASEs that are not affected when an SR protein is 
depleted. First, we examined the binding position on regulated cassette exons for the four 
SR proteins that had the largest number of bound, and regulated, cassette exon events 
(Figure 4.11). This analysis reveals that all four SR proteins have higher binding density 
on activated cassette exons than repressed exons. In contrast, there is a higher density of 
binding to intronic and flanking constitutive exons when the SR protein is involved in 
repression of the alternative exon. Similar to our previous analysis, SR protein binding is 
clustered near the splice sites.  Although, these common patterns of binding exists, 
individual SR proteins still have unique patterns of binding along the AS transcript. For 
example, SRp54 has more broad binding on the alternative exon, whereas B52, XL6, and 
SF2 have more specific, defined binding locations (Figure 4.11).  
These observations were extended when we examined the SR protein binding distribution 
on competing donor AS events (Figure 4.12). SRp54, XL6, and SF2 displayed a higher 
density of binding near the distal 5’ss when the SR proteins activate its usage. Whereas, 
there is higher binding density near the proximal 5’ss when the three SR proteins activate 
its usage.  B52, SRp54, and SF2 also had high binding density near the 3’ss when they  
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Figure 4.10: SR protein binding near splice sites. Relative density of CLIP tags 150nt 
upstream and downstream of the splicing acceptor (3’ss) and splicing donor (5’ss) for 
each SR protein experiment. Wide gray bar is exon sequence and thin gray bar is intronic 
sequence.  
 
activated usage of the distal 5’ss (Figure 4.12). This could indicate that 3’ss selection can 
have an influence on 5’ss selection. 
This analysis reveals that SR proteins bind to specific locations on their target transcripts 
to regulate AS. We observed that SR proteins are bound near the splice sites they 
activate, consistent with the model that SR proteins bind to ESE elements to recruit core 
components of the spliceosome to the proximal splice sites for splice site activation. SR 
proteins are bound to multiple locations on their targets, not ruling out the possibility that 
interactions with themselves, or other splicing regulators, are vital to their regulation of 
AS. 
Unlike RNA-maps determined for NOVA and FOX splicing regulators, the RNA-maps 
for the SR proteins are more widely distributed along the target transcripts [100, 113]. 
This could reflect SR protein control of constitutive and alternative splicing of  
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Figure 4.11: SR proteins bind in a position-specific manner around cassette exons. 
RNA splicing maps showing the relative density of CLIP tags proximal to activated 
(positive y-axis, red), repressed (negative y-axis, blue), and unaffected cassette exons 
(dashed line). The x-axis represents the nucleotide position relative to each splice site. 
The alternative exon is red and the flanking constitutive regions are shaded in blue. The 
total number of regulated events used for the analysis are listed (n).  
 
many transcripts, as well as the more general control of other steps of RNA metabolism. 
SR proteins are dynamically associated with many different complexes throughout 
RNA’s lifecycle, and may bind to different locations to carry out multiple RNA 
processing activities, independent of AS.  NOVA and FOX splicing regulators are tissue-
specific splicing regulators; therefore their RNA-maps are a reflection of their specific 
function on a limited set of targets. A similar observation of broad binding distribution 
was made when RNA-maps were generated for the ubiquitously expressed hnRNP 
proteins in mammals [112]. 
4.4 Discussion 
Recent studies using CLIP techniques to profile direct protein-RNA interactions have 
been instrumental in contributing to the understanding of post-transcriptional regulation. 
CLIP coupled with next-generation sequencing has allowed for the determination of, in 
vivo, protein-RNA interactions genome-wide.  
CLIP-Seq and iCLIP-Seq have been used to profile the protein-RNA interactions of 
multiple splicing regulators, including three members of the mammalian SR protein 
family, but analysis of SR protein binding, and its role in regulating AS, has never been 
studied globally [101, 107, 112].  Using iCLIP-Seq, it was determined that SRSF3 and  
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Figure 4.12: SR proteins bind in a position-specific manner around competing 5’ 
splice sites. RNA splicing maps showing the relative density of CLIP tags proximal to 
activated distal 5’ss (positive y-axis, red), activated proximal 5’ss (negative y-axis, blue), 
and unaffected competing 5’ splice sites (dashed line). The x-axis represents the 
nucleotide position relative to each splice site. The alternatively include region is red and 
the flanking constitutive regions are shaded in blue. The total number of regulated events 
used for the analysis are listed (n).  
 
SRSF4, two mammalian SR proteins, bind to distinct, non-overlapping, sets of 
transcripts. In addition, they were determined to have very different RNA-binding motifs. 
One weakness of this study is that it did not profile RNA-binding with regard to the SR 
protein’s role in regulating AS. Furthermore, only two members of the mammalian SR 
protein family were profiled, so it is not clear if observations for these two SR proteins 
can be extended to the entire family. In order to gain insight into how SR proteins 
regulate AS comprehensively, we used iCLIP-Seq to profile the RNA-binding landscape 
of all eight identified Drosophila SR proteins in S2 cells. 
We identified the nucleotide-resolution mapping of, in vivo, SR cross-link sites. Using a 
statistical algorithm to identify significant clusters of enriched SR protein binding, we 
found that SR proteins bind to, a large set, of similar transcripts.  In addition, we found 
that while different SR proteins can redundantly bind to the same location, most SR 
proteins interact with different RNA sequences.  This finding is consistent with the 
observation that a majority of AS events are regulated, in a combinatorial fashion, by 
multiple members of the SR protein family (Chapter 2).  
Global profiling of the SR protein-binding location on the target genes reveals that SR 
proteins bind, largely, to exonic sequences, and have a slight bias for binding in the 5’ 
	   128	  
UTR.  This observation is consistent with previous analysis that SR proteins bind to 
enhancer elements in exonic regions, and act as general activators of splicing.   
Interestingly, we observed SR protein binding within non-coding RNAs. Many of these 
non-coding RNAs are not processed by the spliceosome, but are regulated by other 
processing pathways.  Previous studies have demonstrated that SR proteins can regulate 
additional RNA-processing events, such as miRNA biogenesis [144]. iCLIP-Seq revealed 
that SRSF3 and SRSF4 interact with long ncRNAs, as well as, short ncRNAs, such as  
snoRNAs. Indeed, one of the major over-represented groups of ncRNAs bound in our 
study were the snoRNAs.  SR proteins are likely required for the splicing of all introns, 
including snoRNA-containing introns.  Even though interaction between SR proteins and 
snoRNA has previously been described, the function of SR proteins, and the processing 
of snoRNAs are unclear. An interesting avenue for further studies would be the 
investigation of the activity of SR proteins in the release of the snoRNA from the intron 
lariat, or, the role of snoRNAs in co-regulation of AS.   
The iCLIP data provided a large number of direct SR protein binding sites, enabling us to 
derive, in vivo, RNA-binding motifs.  Therefore, we identified consensus-binding motifs 
for each SR protein. We found that, in vivo, SR proteins bind purine-rich sequences that 
resemble ESE sequence elements. While some SR proteins share a related motif, others 
have distinct RNA-binding specificities. The RNA-binding motifs for many of the 
mammalian SR protein family members have been identified using, in vitro, SELEX 
procedures. The motifs generated often vary, based on the experimental protocol used.  
Also, because the SELEX sequences are so short, it is difficult to use the identified motif 
to find in vivo targets. The sequence motifs identified in this study are very similar to the 
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binding sequences derived for the SR protein mammalian homologs using SELEX and 
CLIP techniques. This indicates that SELEX is a useful tool for identifying binding 
specificity alone, and that the SR protein binding motifs are conserved between 
Drosophila and mammals. The specificity and accuracy of the derived binding motifs has 
yet to be tested further. It would be interesting to do mutational studies, to determine how 
strict a requirement each derived motif is for SR protein binding and function.  
Finally, we analyzed SR protein binding in respect to its role in regulating pre-mRNA 
splicing. Although SR protein binding is not limited to exons, we found more abundant 
SR protein binding within exons, with increasing density proximal to the splice sites. 
These data agree with model that SR proteins bind primarily to ESEs, and promote 
adjacent splice site recognition.  
When comparing the SR protein binding locations to the outcome of AS, we found that 
SR proteins regulate AS in a position-dependent manner. In particular, cassette exons that 
are activated by SR proteins have a higher frequency of binding, and cassette exons 
repressed by SR proteins have a low frequency of SR protein binding, with higher 
binding density in the flanking introns and constitutive exons. This observation of SR 
protein binding near activated splice sites is extended when we analyzed SR regulated 
competing donor events. There was higher density of binding near the distal 5’ss when 
the SR proteins were responsible for its activation.  These analyses provide insights into 
the mechanism of SR protein AS regulation.  
Our global analysis of SR protein-RNA binding in this chapter shows that SR proteins 
interact with many of the same transcripts, but bind at different locations to regulate post-
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transcriptional processing. SR proteins have specific, conserved, RNA-binding motifs, 
and display position-dependent binding in regards to AS regulation. Although primarily 
known as splicing regulators, the observation of binding to diverse classes of RNAs, 
including ncRNAs, implies SR proteins may have a broad, yet unidentified, role in many 
RNA processing events.   
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Chapter V: Perspectives and Conclusions 
5.1 SR proteins and human disease 
The precise control of AS, and other RNA processing steps, by RBPs is essential for 
proper protein expression in higher eukaryotes, and is utilized as a post-transcriptional 
mechanism of gene expression regulation. Computational predictions and transcriptome 
profiling of many normal and diseased tissues indicate that a high fraction of diseases are 
caused by mutations that alter splicing. It has been estimated that 15% of mutations that 
cause genetic disease affect conserved splicing signals, including elements recognized by 
SR proteins [17]. 
Elevated SR protein levels have been observed in a variety of human tumors, and 
correlate with cancer progression [25]. SRSF1 has been shown to regulate Ron 
(macrophage-stimulating 1 receptor) splicing that produces a constitutively active 
isoform, which contributes to increased cell motility and tumor metastasis [147].  HIV-1 
uses, multiple, competing 5’ and 3’ splice sites to generate more than 40 mRNAs. 
Various SR proteins have been shown to regulate these splicing events in HIV-1, and 
may be a target for inhibition [148]. The inherited neurodegenerative disorder SMA 
results from a deletion of the SMN1 locus. A single polymorphism in the paralogous 
SMN2 gene increases skipping of exon 7, resulting in a decrease in the production of 
functional SMN protein. The single nucleotide change is thought to disrupt an SRSF1 
ESE, which prevents SR protein binding, and subsequent activation of inclusion of exon 
7 [18].  SR proteins have also been demonstrated to be autoantigens in systemic lupus 
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erythematosus (SLE), and have regulatory roles in the splicing of CFTR, that is the gene 
mutated in cystic fibrosis patients [149, 150].  
Disruption of SR protein function contributes to the progression of many human diseases, 
however the complexity of the RNA targets, specificity of RNA-binding, and precise 
mechanism of AS regulation remains poorly understood for many members of the SR 
protein family.  With the emergence of genome-wide methods to profile changes in AS, 
and detecting protein-RNA interactions, a global understanding of SR protein function is 
possible. In this dissertation we present genome-wide analysis of AS regulation, and 
RNA-binding information, for the full family of SR proteins. Hopefully, a clear 
understanding of SR protein regulation of AS can contribute to the development of novel 
therapies, or diagnostic approaches, for human disease.  
5.2 Combinatorial regulation of AS by the SR proteins 
SR proteins are identified by having similar protein domain architecture, and their ability 
to complement splicing-deficient S100 extracts. Since multiple SR proteins could 
substitute for one another in the splicing of in vitro substrates, it was thought that SR 
proteins were redundant regulators of splicing [130]. However, the observation of 
embryonic lethality for many individual members of the SR protein family, and further 
studies demonstrating that specific SR proteins were required for the regulation of 
splicing of certain pre-mRNAs, a specific role for individual SR proteins in splicing was 
uncovered. However, a comprehensive, genome-wide, study of AS regulation for the SR 
proteins has never been performed.  
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In chapter two, we profiled the changes in AS when individual SR protein expression was 
reduced using RNA-Seq. We identified 561 simple AS events regulated by the eight SR 
proteins in Drosophila S2 cells. We found that multiple members of the SR protein 
family regulate a majority of these AS targets. In addition, we found that SR proteins co-
regulate the AS of the targets in the same direction, and that there is very little anti-
regulation between the SR protein family members.  These discoveries extend the 
observation of overlap in AS targets between two SR proteins in a previous study, and 
would have been missed with the analysis of a single SR protein [116].  
By analyzing the magnitude and direction of splicing change when the expression of two 
SR proteins are knocked-down together on co-regulated targets, we revealed that the 
contribution of individual SR proteins are additive, and the combination of SR protein 
regulation results in the final pattern of AS observed. The expression of two SR proteins, 
or any RBPs, reduced at the same time has never been profiled with respect to AS. 
Therefore, it would be interesting to see if this combinatorial mechanism of regulation 
can be extended to other splicing regulators.  
Using RNA-Seq we can monitor other changes in the transcriptome, when an SR protein 
is depleted, in addition to AS. We found that SR proteins could regulate promoter choice, 
poly(A) site usage, and overall transcript levels of specific genes. SR proteins are 
presumably regulating these events independent of their canonical interactions with the 
spliceosome.  It has been demonstrated that SR proteins can associate with the CTD of 
RNA Pol II, and that other splicing regulators can associate with the cleavage and 
polyadenylation machinery to influence APA [120]. Since splicing and 3’ end processing 
can occur co-transcriptionally, it will be interesting for further studies to identify the 
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mechanism of SR protein regulation of these events, and potentially identify further 
cross-regulation between transcription and downstream RNA-processing steps. 
5.3 AS regulation requires an RS-domain, and specificity is determined by the 
RRM-domain 
SR proteins have a modular protein domain structure, consisting of an N-terminal RNA-
binding domain (one or two RRM-domains) and a C-terminal domain rich in 
arginine/serine repeats (RS-domain). In order to regulate AS, it has been shown that SR 
proteins bind RNA through the RRM-domain, and recruit spliceosomal components 
through protein-protein interactions via the RS-domain. However, previous studies have 
shown that the RS-domain can contact the RNA, and that the RS-domain is dispensable 
for the regulation of certain splicing events [133, 137]. One major flaw of these studies is 
that they were performed using a small number of in vitro splicing substrates.  
Having identified numerous endogenous AS targets of the SR proteins in chapter two, in 
chapter three we sought to analyze the contribution of the SR protein domains to AS 
regulation in vivo.  We found that in order to regulate AS in vivo the SR protein XL6 had 
to have an RS-domain. Additionally, when we substituted the RS-domain from another 
SR protein, B52, we found that it could functionally substitute. This is consistent with 
previous observations of functional RS-domain substitution. However, when we profiled 
AS events that are regulated antagonistically by XL6 and B52, we found that the fusion 
protein with the substituted RS-domain regulated the splicing pattern in the same way as 
XL6. This provides evidence that the RRM-domain, not the RS-domain, is responsible 
for determining the magnitude and direction of splicing. In addition, the fusion protein 
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did not regulate targets that were only affected by B52, meaning that specificity is also 
determined by the RRM-domain.  
These observations demonstrate the importance of the RS-domain for SR protein AS 
regulation, in vivo.  It also extents the observation that the RS-domains can be 
functionally substituted for one another, to the Drosophila SR proteins. Additionally, the 
RRM-domain determines the specificity and pattern of AS. Therefore, most likely, the 
RNA-binding location on the target transcript ultimately determines the magnitude and 
direction of splicing, and not the RS-domain. In the future, it would be interesting to 
examine if this behavior extends to all the SR proteins in Drosophila, and SR proteins in 
other species. It will also be interesting to use these in vivo targets to see how post-
translational modifications of each of the SR protein domains also plays a role in 
regulating AS. 
5.4 Global RNA-binding landscapes of the SR proteins  
The observations that SR proteins cooperate with each other to regulate splicing targets, 
and that the RNA-binding domain contributes to the specificity and direction of splicing 
change, we sought out to map the global protein-RNA interactions in chapter four. 
Several in vitro approaches to identify SR protein targets have been performed, and 
previous studies have mapped the global, in vivo, protein-RNA interactions of three 
mammalian SR proteins. However, there has never been a systematic profile of most 
members of the SR protein family, and there never has been a study examining, in vivo, 
SR protein binding with regards to the regulation of endogenous AS.  
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Using iCLIP-Seq, we were able to map SR protein binding with high precision, and 
found that SR proteins bind to most transcripts in S2 cells. This is likely since SR 
proteins are not only important for the regulation of AS decisions, but are required for the 
regulation of constitutive splicing. This is also consistent with the study of other 
ubiquitously expressed splicing regulators, such as the hnRNP family [112]. Despite 
binding to many of the same genes, SR proteins are able to bind to distinct locations on 
the genes, often in multiple locations. The binding to genes not regulated at the level of 
AS, or SR protein binding to regions far away from the splice sites, indicate the possible 
role of SR proteins in the regulation of other RNA-processing steps. Indeed, similar to 
reports for mammalian SR proteins, we observed SR protein binding to many types of 
ncRNAs [107]. It remains to be investigated whether SR proteins are required for the 
processing of many ncRNAs. An interesting possibility is that the interaction with the 
ncRNAs can influence SR protein regulation of splicing.  
The large number of in vivo binding sites generated by iCLIP-Seq allowed us to derive, in 
vivo, binding motifs for the SR proteins. We found that all SR proteins bind to purine-
rich sequences that resemble ESEs. Some SR proteins have, distinct, specific motifs, 
while many of the SR proteins binding motifs are related. In addition, the motifs derived 
in chapter four resemble binding motifs derived for many of the mammalian SR protein 
homologs, suggesting conservation of SR protein binding motifs between Drosophila and 
mammals. The functionality and strict requirement for the SR protein binding motifs in 
the regulation of AS remains will need to be further investigated. Also, it would be 
interesting to identify if any of the derived binding motifs contribute to RNA secondary 
structure, especially since B52 has been shown to bind a hairpin loop structure [146]. 
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Finally, we integrated our binding data with the AS information, and were able to build 
splicing RNA maps. As a whole, the RNA maps revealed that SR proteins primarily were 
associated with exonic sequences, and were bound near the splice sites that they 
activated. This is consistent with the notion that SR proteins are exonic splicing 
enhancers, and activate splicing by recruiting spliceosomal components to the nearby 
splice-sites.  
Taken together our global analysis of SR protein binding shows that these proteins are 
multifunctional by binding to diverse classes of RNAs, and can regulate both constitutive 
and alternative exons by binding exonic regions near the activated splice site.  
5.5 Final thoughts and future directions 
In this dissertation we identified, genome-wide, the endogenous targets of AS, and the 
binding distribution of all eight SR proteins identified in Drosophila. We found that SR 
proteins regulate AS in a combinatorial manner, and bind to exonic regions near splice 
sites to activate splice site selection. Initially identified as splicing regulators, we found 
that SR proteins bind to a diverse set of RNAs, including ncRNAs, and can also regulate 
promoter and poly(A) site selection. This suggests a network of interactions, and 
extensive coupling, of different cellular programs that control gene expression. It also 
uncovers, yet identified, functions for SR proteins in other RNA-processing steps. These 
findings have defined the precise global regulatory network for the SR proteins, and 
provided insights into the molecular mechanism of SR protein AS regulation, and gene 
expression control.  
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In future studies, it will be interesting to examine if this type of combinatorial regulation 
exists beyond the SR protein family, and can be extended to many different types of 
splicing regulators. Many AS events are regulated tissue specifically, or at precise 
developmental time points, and can contribute to disease progression if misregulated. 
Examination of the expression pattern of SR proteins in different tissues and 
developmental conditions may reveal the precise mechanism of regulation of many AS 
events important for development and tissue homeostasis, and could provide novel targets 
for the treatment of disease.  
In addition to SR protein’s roles in the regulation of AS, they can regulate many other 
processes that may be coupled to AS regulation. Although we identified targets where SR 
proteins affect promoter selection, polyadenylation site choice, and binding to noncoding 
and intronless RNAs, the precise mechanism of regulation has not yet been identified. It 
will be interesting to assay the interaction between SR proteins and other regulatory 
complexes important in other gene expression regulatory networks.  
Fully understanding SR protein regulation beyond AS will allow greater understanding of 
the integration of gene expression regulation between multiple regulatory networks, and 
may identify SR proteins not only as AS regulators, but master regulators of gene 
expression in higher eukaryotes.   
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